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ABSTRACT

Lyme borreliosis, more commonly referred to as Lyme disease, is the
fastest growing zoonotic disease in North America with approximately 30,000
confirmed cases and 300,000 estimated infections per year. In nature, the
causative agent of Lyme disease, the bacterium Borrelia burgdorferi, cycles
between Ixodes sp. ticks and small mammals. Humans become infected with
Lyme disease after being bitten by an infected tick. The primary indicator of a
Borrelia burgdorferi infection is a bull’s eye rash typically followed by flu-like
symptoms with treatment consisting of a 2-4 week course of antibiotics. If not
treated, later stages of the disease can result in arthritis, cardiovascular and
neurological symptoms. Diagnosis of Lyme disease is challenging and
currently requires a complex laboratory diagnostic using indirect detection of
host-generated antibodies by a two-tiered approach consisting of an enzyme
linked immunosorbent assay (ELISA) followed by IgM and IgG immunoblots.
Although two-tier testing has provided an adequate approach for Lyme
disease diagnosis, it has weaknesses including subjective analysis, complex
protocols and lack of reagent standardization. Immuno-PCR (iPCR) is a
method that combines ELISA-based detection specificity with the sensitivity of
PCR signal amplification and has demonstrated increased sensitivity for many
applications such as detection of disease biomarkers but has yet to be applied
for diagnosis of Lyme disease.
Herein, using iPCR and recombinant B. burgdorferi antigens, an assay
for both the direct and the indirect detection of Lyme disease was developed
iii

and demonstrated improved sensitivity for detection of B. burgdorferi
antibodies using a murine model. Moreover, we present evidence using
human Lyme disease patient serum samples that iPCR using both multiple
antigens and a unique single hybrid antigen is capable of achieving increased
sensitivity and specificity compared to existing methodology. These data
represent the first demonstration of iPCR for Lyme disease diagnosis and
support the replacement of two-tier testing with a more simplified and
objective approach.
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CHAPTER ONE:
INTRODUCTION

Lyme Disease Background
History
Beginning in the early 1970s, a cluster of apparent rheumatoid arthritis
cases occurring primarily among children and some adults in the areas
surrounding Lyme, Connecticut captured the attention of the public health
community. A surveillance of the town resulted in 39 children diagnosed with
reoccurring symptoms of large joint swelling and pain with some episodes
lasting for extended periods of time [1]. An additional twelve adults either
related or living in close proximity to the arthritic children were also diagnosed
with signs and symptoms similar to those seen in the juvenile cases. The
investigation excluded juvenile rheumatoid arthritis as the cause of the
epidemic on the basis that the prevalence of symptoms (particularly arthritis)
was 100 times greater than that expected for juvenile rheumatoid arthritis for
the surrounding Connecticut communities. The disease was initially named
Lyme arthritis to indicate the town and initial symptom observed. Following an
expansion of the clinical symptoms to involve both neurological and cardiac
symptoms, the name was finally changed to Lyme disease [2].
The growing investigation revealed that about 25% of the patients had
developed an erythematous cutaneous lesion that appeared to expand into a
reddish rash composed of concentric rings similar in appearance to a ‘bull’s
eye’. The lesion typically appeared weeks before the onset of disease
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symptoms and resembled a similar lesion that had been described much
earlier in Europe that was associated with being bitten by an Ixodes rincinus
tick [3]. Investigators followed patients with cutaneous lesions [4] and
subsequently observed a range of symptoms including arthritis, neurological
and cardiac abnormalities [5]. The addition of neurological and cardiac
involvement underscored the complex manifestation of the disease that
appeared to involve multiple organ systems [2, 5].
The evidence presented for the European rash and its association with
a tick bite led to a similar hypothesis in the Connecticut cases that a local
Ixodes species was associated with the disease [6]. This conclusion was also
further supported by the fact that many of the children diagnosed with arthritis
either lived or routinely played adjacent to wooded areas where Ixodes ticks
were commonly found. It was also noted that the children’s initial symptoms
typically started during the summer months, which coincided with the peak of
tick season. Many of the children reported having a skin rash similar in
description to an erythema migrans (EM), or ‘bull’s-eye’ rash prior to
developing arthritis that was often associated with a tick bite [1]. Another
important piece of supporting evidence was that patients exhibiting the EM
rash that were treated with penicillin showed a shortened duration of the rash
and lessened subsequent arthritis [7]. The affective treatment of the disease
with antibiotics provided a key piece of evidence that a bacterial infection was
most likely associated with disease progression [7].
Similar studies at the time surrounding a suspected epidemic of
babesiosis caused by a parasite in Shelter Island, New York provided the next
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critical step in unravelling the cause of the disease. Dark field microscopy of
organisms isolated from Ixodes scapularis adult ticks collected as part of a
serosurvey for the Shelter Island cases identified coil shaped bacteria known
as spirochetes in the samples. These bacteria were further cultured and
confirmed in a spirochete specific medium thus confirming the presence of the
organism. Serum from individuals exhibiting symptoms of Lyme disease from
the Connecticut group were then tested using the tick isolated organisms and
showed strong sero-reactivity to the newly cultured spirochetes [8]. This
indicated the Lyme disease patients had most likely been infected with the
same organism. The final piece of evidence was uncovered when the same
tick isolated spirochetes that exhibited sero-conversion in Lyme patients were
also isolated from skin samples of patients with the EM rash [9]. Further
investigations also isolated the same organism from white-footed mice in the
local Connecticut communities [10] thus identifying the main reservoir of the
bacterium [11]. With the reservoir identified and reisolation of the causative
bacteria from human patients exhibiting the characteristic EM, a strong
explanation for the arthritis epidemic observed in areas surrounding Lyme,
Connecticut had been determined. The future of Lyme disease research
would now focus on the biology of the bacteria, transmission, human infection
and diagnosis of the disease.
Lyme Disease Infection
Historically, there have been approximately 30,000 confirmed cases of
Lyme disease per year seen across almost every state with the majority of
3

cases concentrated in the Northeastern and Midwestern states [12].
Representative statistics for the CDC confirmed cases of Lyme disease in
2011 are depicted by state in Figure 1. More recently, the CDC has revised
these statistics to suggest an approximate estimate of 300,000 infected cases
per year [13].
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Figure 1. United States 2011 CDC confirmed Lyme disease cases. Cases are determined based on the state of residence and
not the state where the infection was contracted. Case number ranges are depicted based on the color scale with the exact
number of cases listed by State in the bottom table [14, 15].
5

The primary indicator of Lyme disease infection by the B. burgdorferi
spirochete is the appearance of an EM or ‘bull’s eye’ rash that is typically
observed in approximately 75% of cases [16]. An oval or circular rash can be
observed over days or weeks following a tick bite that begins as a small red
spot at the site of the bite [6]. More specific to Lyme disease, the rash
continues to form a red ring surrounding a clear area with a red spot in the
center very similar in appearance to the concentric circles of an archery
target. The rash, which typically occurs at the site of the tick bite, can take a
few weeks to fully present in infected patients and can vary in size from a
silver dollar to covering the entire surface of the torso [17]. Following the
spread of infection, additional similar rashes both with and without a bull’s eye
center can manifest at additional locations distal to the original tick bite and
indicate dissemination of the Lyme disease spirochete [18]. Although the
bull’s eye rash is the hallmark symptom of Lyme disease, other symptoms
similar to common viral infections such as fever, aches, stiffness and fatigue
can accompany infection and can last for longer periods of time than other
common infections [19]. Assuming the infection goes untreated and following
organism dissemination, additional symptoms can be observed including
arthritis, nervous system complications and more rarely can involve cardiac
symptoms as well [20]. In even rarer cases, B. burgdorferi infection has been
documented to cause severe fatigue [21], eye inflammation [22] and hepatic
liver disease [23].
Recommended treatment for Lyme disease is a 2-4 week course of
antibiotics [24]. Although typically successful at resolving the infection,
6

approximately 15% of patients will continue to experience symptoms of
muscle and joint aches or fatigue following treatment [25]. Pain symptoms
can sometimes persist for 6 months or more following treatment after which
the disease is often referred to as ‘Chronic Lyme Disease’ due to the inability
to resolve symptoms with standard antibiotic treatment [25]. If symptoms
persist following treatment the condition is more appropriately being referred
to as ‘Post-treatment Lyme Disease Syndrome’ (PTLDS) [26]. Although the
cause of PTLDS remains elusive, it has been suggested that unresolved
symptoms result from residual tissue damage due to overstimulation and/or
self-recognition of the immune system resulting from the original spirochete
infection [27]. Lyme disease is suspected to be similar to other human
infections including Chlamydia [28] and Campylobacter [29] in which similar
‘auto-immune’ reaction based diseases have been observed following
successful treatment of the infection. In direct contrast to the residual tissue
damage theory, additional theories have been postulated that unresolved
symptoms are a reflection of persistent infection with Borrelia burgdorferi that
was not cleared with an initial course of antibiotics [30]. Select groups of
health care providers have advised their patients that based on this theory
their conditions warrant a longer term regimen of antibiotic treatment beyond
the recommended 2-4 week course of treatment [31]. This is in direct
contradiction to studies that have demonstrated that Lyme disease patients
who received prolonged courses of antibiotics did not result in an outcome
significantly better than patients treated with a placebo [32, 33]. Regardless
of the cause of PTLDS, it continues to be a controversial issue [34] that
7

underscores the importance and strong need for improved Lyme disease
diagnosis.
Ixodes scapularis Life Cycle
The only known insect vectors of Lyme disease in the United States
are Ixodes scapularis, commonly known as the deer or black-legged tick in
the Eastern part of the United States and the closely related Ixodes pacificus
or western black-legged tick in the Western part of the United States [35].
Approximate distributions for each species are shown in Figure 2. I.
scapularis and I. pacificus are both hard-bodied ticks that display a two-year
life cycle that is dependent on a fresh blood meal from a vertebrate to
advance to the next stage in each cycle [36].

Figure 2. Black-legged tick distribution. States where each species can be
found are shown [15, 37].
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The deer tick proceeds through three distinct stages of growth over its
life cycle that includes the larval, nymph and adult stages (Figure 3). It takes
approximately two years for the tick to proceed from an egg through all three
developmental stages, reproduce, subsequently lay eggs and ultimately
expire at the end of the cycle [38]. The tick life cycle begins with egg hatching
and emergence of larvae in spring. This is then followed by development into
nymphs the ensuing year after the first blood meal and finally by development
into adults the subsequent year after the second blood meal [39]. B.
burgdorferi infection is acquired from infected nymphs or adults with
uninfected larvae posing no danger to humans due to the absence of the
infecting organism [40]. People are usually able to notice attached and
feeding adult ticks making them easy to remove prior to spirochete infection.
A large number of Lyme disease cases originate from feeding nymphs that
are smaller and more difficult to notice. Hence, the majority of Lyme disease
cases are reported during the summer months with very few cases reported in
the spring and fall [39].

9

Figure 3. Black legged tick life cycle. The two-year life cycle of the Ixodes tick
begins with eggs laid by the female in spring that proceed to hatch into larvae
that partake of their first blood meal in the summer. This is followed by
molting into the nymph form that then overwinters and remerges the following
spring and again partakes of a blood meal followed by molting into the adult
form that feeds a third time in late fall or early spring of the second year and
followed by egg laying in late spring and a repetition of the cycle.

The larval form comprises the first stage of the tick infectious cycle
[41]. The adult female Ixodes tick lays its eggs in the spring, which then hatch
into larvae during late summer. The larvae, which are no bigger than a pin
head, begin to peak in activity in late August [42]. A small mammal or bird
that contacts the awaiting larvae on the ground then becomes the first host for
the tick in the first stage of its life cycle. The larva uses its mouth-parts to
attach to the host and then begins its first blood meal. Over a period of 3-5
days the tick swells with the blood meal from the host [38]. It is at this stage
10

that the spirochete can make its first transfer between hosts. If the mammal
or bird had been previously infected with the organism from a subsequent tick
bite, the larva would now become infected with the Lyme disease spirochete.
The spirochete utilizes large numbers of wild infected hosts (such as whitefooted mice) as a reservoir that can continue to infect new larvae through
each transmission cycle [43]. Although mice and other small mammals are
the principal reservoir for B. burgdorferi, ground-feeding birds can serve as
natural reservoirs as well [44]. Since larval ticks require a blood meal to
become infected, freshly hatched larvae cannot transmit Lyme disease to
animals or humans and hence pose no danger for passage of the disease.
Instead, larvae act as the first stage of the infectious life cycle through feeding
on ‘reservoir’ hosts. Once a larvae has fed, it will not feed again until the next
stage in its life cycle [45].
The second stage of the tick life cycle poses the largest threat of
human infection and is characterized by the nymphal form of the tick [45].
After completing their blood meal at the end of the first stage in their life cycle,
the larvae disassociate from their host and return to the ground where they
molt and metamorphose into nymphs. This occurs at the end of the fall after
which the nymphs become dormant through the winter and early months of
spring. Typically around May, the nymphs awaken from their inactive
overwinter state, climb onto nearby vegetation and await the opportunity to
interact with a new small mammal or bird host as they pass by [46]. The
nymph takes the opportunity to attach to the host animal on which it will feed
for approximately five days. During feeding, the nymph will engorge with
11

blood and swell many times its original size. If the nymph had been infected
during its blood meal in the larval stage, it can transmit infectious B.
burgdorferi to its new host after about 48 hours of feeding [47]. Similar to the
larval stage, if the nymph is uninfected at this point in its life cycle, it can
become infected if its host already carries the Lyme disease pathogen from a
previous infectious tick bite. Surveys of ticks in the highly endemic Northeast
and upper Midwest have found that about 25% of nymphs contain and can
transmit B. burgdorferi [48]. Regrettably, because of frequent outdoor activity
during the spring months, humans will often come into contact with
populations of infected nymphs during their peak activity, which can occur
from late May to the end of July. Nymphs normally feed on small mammal
and bird hosts but will feed upon humans, pets and other domestic animals if
the opportunity presents itself. Although not as small as larvae, nymphs
reach the size of about a poppy seed [39] which makes them difficult to notice
when they are attached to visible areas on the skin and even more difficult to
locate in less conspicuous areas of the body such as the scalp or armpits.
Hence, nymphs are responsible for transmission of a large proportion of
human Lyme disease cases [45].
The third and last stage of the tick life cycle involves progression to the
adult form followed by reproduction. After finishing its blood meal, the nymph
releases from its host, falls to the ground and begins the process of molting or
transforming into the adult and reproductive stage of its life cycle [49]. After
completing development in early fall, the adult tick climbs and perches on
vegetation a few feet off the ground and awaits another host such as a deer or
12

other large mammal to complete its last blood meal. Late October and early
November mark the peak of activity for adult tick feeding [50]. Due to the
increased potential for infection at either the larval or nymph stage, a higher
percentage of adult ticks surveyed in endemic areas have been found to be
infected with B. burgdorferi with as much as 50% of the population in the
Northeast testing positive for the Lyme disease spirochete [51]. In contrast to
infection by bites from nymphs, fewer cases of Lyme disease are associated
with adult tick bites because of their larger size. When fully engorged with a
blood meal, adults can reach the size of a small grape and hence are much
more likely to be detected and removed prior to the 36 hours required for
disease transmission [52].
At the end of the fall and beginning of the winter months, both fed and
unfed adult ticks migrate underneath ground cover and surface vegetation to
overwinter. Adult ticks become inactive in temperatures below 45° F which
means winter temperatures in the endemic Northeast and upper Midwest
states keep ticks inactive in a dormant state until temperatures rise again in
late February to the beginning of March [53]. As the temperature warms,
adult ticks will again resume their attempts to acquire a host blood meal prior
to actively seeking a mate for reproduction which peaks in typically March to
the beginning of April [41]. Tick mating in the spring can occur either while
attached to a host or following a blood meal and is followed by the laying of
eggs by the female underneath leaf litter and other ground cover. An adult
female tick can lay up to 3,000 eggs in a litter after which she will die and the
eggs will hatch later that summer completing the two-year life cycle [54].
13

Borrelia burgdorferi Biology
Borrelia burgdorferi, the causative agent of Lyme disease in the United
States is a spirochete bacterium that appears gram negative by safranin
staining, but is not typically classified as either gram positive or negative [55].
The other two Lyme disease causing species of the genus Borrelia are B.
garinii and B. afzelii, which are responsible for the majority of cases in Europe
[56]. Of the three species, B. burgdorferi is unique in that it has an extensive
distribution encompassing most of the northern hemisphere including both
North American and Europe [57]. B. burgdorferi is transmitted by ticks,
requires small mammals as hosts to complete its life cycle and causes
disease in humans and other mammals by causing an inflammatory response.
The bacteria are able to adapt to the mammalian environment by dramatically
up-regulating or down-regulating gene expression as it is transmitted from the
infected tick to the mammalian host [45].
B. burgdorferi causes a primary infection by moving into the
bloodstream of the infected mammal and colonizing different tissue sites.
Through chemotaxis and unique mechanisms of motility, the organism
continues to disseminate throughout the body leading to a more advanced
stage of infection [58]. A number of B. burgdorferi proteins have been
implicated in host cell adherence through interactions with surface proteins
and extracellular matrix components. As a result of these proteins, the
organism is capable of blood vessel penetration, adherence to endothelial
cells and interacting with a number of different tissues [59]. For example, B.
burgdorferi stimulates plasmin on the bacterial surface and has the capability
14

to induce host protease production which aides in its dissemination and
ultimately leading to tissue damage and inflammation [60]. B. burgdorferi
infection can lead to arthritic, dermatological, cardiovascular and neurological
symptoms across the multiple stages of infection in spite of low numbers of
microorganisms in tissues [61]. Unique mechanisms to evade the immune
system allow the spirochete to persist for long periods of time post infection in
the presence of strong antibody and cellular host responses [62].
Interestingly, the pathogen has not been shown to produce any toxins to aide
its persistence and disease manifestation over either short or extended time
periods [45].
Much of the adaptive nature of the organism is attributed to its unique
genome [63]. Sequencing of the B. burgdorferi genome confirmed the
presence of an approximately 900 kilobase pairs (kbp) linear chromosome
and an extra-chromosomal complement of linear and circular plasmids in the
range of 55-220 kbp [64]. The genome sequence for multiple strains of all
three Lyme disease causing Borrelia species (B. burgdorferi, B. afzelii, B.
garinii) [65, 66] as well as multiple related species (B. hermsii, the causative
agent of relapsing fever) [67] have been completed or are currently underway.
A large number of housekeeping genes, which are conserved in sequence
and organization across the genus, are carried on the chromosome. The up
to 22 circular and linear plasmids, which can vary in number by
species/isolate and are much more variable in sequence than the
chromosome, encode a large number of differentially expressed surface
proteins known to interact with the B. burgdorferi tick vector and mammalian
15

host [68]. One of the more studied strains is the B. burgdorferi B31 type
strain, which possesses nine circular and twelve linear plasmids and a small
linear chromosome. Beyond coding gene sequences, B. burgdorferi plasmids
are unusual in that they contain a large number of paralogous and
pseudogene sequences as well as genes essential for host infection [63]. In
addition, many genes have been experimentally deleted from B. burgdorferi
plasmids with no resulting detectable phenotype [69].
B. burgdorferi has been shown to modulate its expression profile in
response to the numerous environmental cues encountered throughout its
infectious cycle and can therefore demonstrate variation in antigen
presentation throughout infection [70-86]. For example, during early stages of
infection B. burgdorferi is capable of attachment to host tissues through
expression of different adhesins that can bind integrins [87], fibronectin [88,
89], proteoglycans [90], glycosaminoglycans [91] and laminin [92]. B.
burgdorferi has also been shown to express proteins known as complement
regulator-acquiring surface proteins (CRASPs) that bind factor H and prevent
the spirochete from being killed by the complement arm of the innate immune
system [93]. Crucial to clearance of the pathogen in the mammalian host is
development of a humoral or antibody response against specific B.
burgdorferi antigens [94]. Several well-known immunodominant antigens are
expressed by B. burgdorferi early in disease including flagellin [95], OspC [96]
and BmpA [97]. As the disease progresses further resulting in spirochete
dissemination, additional antigens are known to illicit an immune response as
determined by immunoblot [98, 99]. B. burgdorferi has been shown to also
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utilize the VlsE lipoprotein which undergoes antigenic switching through a
recombination mechanism to further avoid the immune system [100] and
consequently this protein has proved useful as an immunodiagnostic target
[101]. More recent studies have focused on screening large numbers of B.
burgdorferi proteins using protein arrays with the aim of discovering antigens
that illicit a strong immune response [102] toward the ultimate goal of
contributing to development of the next generation of Lyme disease
diagnostics.
Current State of Lyme Diagnostics
Due to the fact that Lyme disease can present with symptoms like
fever, pain and fatigue which are very similar to other common illnesses,
treating physicians may have difficulty diagnosing a B. burgdorferi infection
based on these symptoms alone [103]. Although the ‘bull’s eye’ rash or EM is
the only unique Lyme disease symptom it is only typically detected in about
75% of patients infected with B. burgdorferi and can be difficult to detect
based on size and/or location on the head or torso [17]. To further complicate
the diagnosis, people may not recall or detect the actual tick bite required for
transmission of the pathogen. This is typically due to the fact that many
people are bit by the Ixodes tick in the nymph stage, which is small and
difficult to detect [104]. Assuming symptoms match that of Lyme disease and
in the absence of an EM rash, physicians will then rely on a detailed medical
history to rule out additional potential infectious agents and/or diseases. The
physician will look for specific details relating to B. burgdorferi exposure
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including if the person frequents areas endemic for Lyme disease, if a tick bite
was detected or suspected and what part of the year symptoms first appeared
(i.e., summer months). This information is then combined with a thorough
physical examination for evidence of tick bites and laboratory diagnostic tests
that are used to further aide in diagnosis [105].
Two-Tier Laboratory Diagnostic
The accepted method of Lyme disease laboratory diagnosis is indirect
detection of host generated antibodies to Borrelia burgdorferi, the causative
agent of the disease [106]. It takes days to weeks for an individual infected
with B. burgdorferi to generate sufficient IgM or IgG antibody titers,
respectively, against the bacteria to be detected using laboratory based
diagnostics [107]. The current accepted method of serologic testing for Lyme
disease utilizes a 2-tier approach that was established in 1995 [106]. The
method entails testing of a serum sample using a first-tier enzyme linked
immunosorbent (ELISA) assay employing B. Burgdorferi whole cell sonicate
or recombinant antigens that results in high sensitivity but somewhat reduced
specificity. A negative first-tier result means no further testing of the
specimen is recommended. A positive first-tier result is followed by retesting
of the serum sample by distinct IgM and IgG immunoblots (or western blots)
that typically employ B. burgdorferi whole cell sonicate. An individual is
considered to be diagnostically positive for Lyme disease only if the ELISA
(first-tier) and the immunoblot (second-tier) are both positive.
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Each step of two-tier testing requires different analytical criteria and
subsequent results are either quantitative (ELISA) or qualitative (immunoblot)
based on the tier. The first-tier ELISA measures a quantitative immune
response to typically a single B. burgdorferi antigen or immunogenic peptide
or a limited number of recombinant B. burgdorferi antigens. Increased values
are typically correlated with the numbers of B. burgdorferi antibodies in the
serum and provide a measure of immune response level. First-tier results are
categorized as positive, equivocal or negative based on pre-established value
ranges [108]. Second-tier testing using IgM and IgG immunoblots provides a
qualitative measurement of antibody response and typically employs the use
of B. burgdorferi whole cell sonicate [99]. There are a small number of kits
approved for use as a second-tier Lyme disease diagnostic that employ
multiple recombinant B. burgdorferi antigens [109]. Second-tier IgM
immunoblot results are considered positive if two of three B. burgdorferi
specific bands (23, 39 and/or 41 kDa) are detected above a particular signal
threshold [106]. Second-tier IgG immunoblot results are considered positive if
five of ten B. burgdorferi specific bands (18, 21, 28, 30, 39, 41, 45, 58, 66
and/or 93 kDa) are detected [106]. Immunoblot second-tier testing employed
during the first 4 weeks of disease includes testing of both IgM and IgG
antibody reactivity. Due to the likelihood of a false-positive test result for IgM
indicating a false active infection in later stage patient samples, IgM
immunoblot results are not considered reliable for patients with suspected
illness greater than 4 weeks in duration [110].
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Two-tier testing has provided an adequate approach for Lyme disease
diagnosis but suffers from certain weaknesses including the subjectivity and
complexity of immunoblot analysis as well as non-standardized lysate
preparations and antigen sources [111]. For these reasons, immunoblot
analysis and two-tier results have been shown to vary from laboratory to
laboratory based on the test strategy used for detection of host antibodies
resulting from the particular kit used [112]. Differences between test results
largely reflect the antigen variability across different manufacturers [111]. As
detailed above, B. burgdorferi antigen expression can vary significantly based
on the strain and the conditions used to cultivate the organism. More
recently, in an effort to standardize the antigens used between Lyme disease
diagnostics it has been suggested that the use of whole cell sonicate as a
source of antigens be replaced with the utilization of a combination of
recombinant B. burgdorferi antigens [109]. Although a single antigen would
further simplify a diagnostic test for Lyme disease, no single antigen tested to
date has shown success at diagnosing Lyme disease across all stages of the
disease [111]. A more recent ELISA that targets the conserved VlsE C6
peptide of B. burgdorferi has been developed and proposed as a single-tier
test. Although it appears to provide increased sensitivity for early stage
disease diagnosis, the antigen shows no increased sensitivity for later-stage
disease diagnosis with overall lower specificity observed when compared with
two-tier testing [113]. Hence, despite its drawbacks, two-tier testing remains
the recommended and current method for laboratory diagnosis of Lyme
disease [114].
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Additional Methods For Diagnosis Of Lyme Disease In Development
Although two-tier testing remains the mainstay of clinical Lyme disease
diagnostics, it is important to emphasize that additional methods have been
developed and tested. These methods include both direct detection of the
presence of spirochetes and indirect detection by serological methods. Direct
methods include microscopic observation of whole spirochetes from patient
samples, detection of B. burgdorferi-specific antigens, in vitro culture of
spirochetes from patient samples and polymerase chain reaction amplification
(PCR) of spirochete nucleic acid targets [111]. Dark field microscopy is useful
for specimens where large numbers of spirochetes are expected but the value
of diagnosis by microscopy in the clinical laboratory is limited due to the low
organism density in clinical samples and similarity to host tissue structures
[55]. Direct detection of B. burgdorferi antigens by ELISA and dot blot is
rarely used in a clinical setting due to low sensitivity [115] and poor specificity
and reproducibility [116]. Culture of B. burgdorferi from patient samples is
also not routinely used in a clinical setting due to variations in in vitro growth
medium, long sample incubation periods (minimum of 12 weeks), and most
importantly very low sensitivity due to small numbers of spirochetes present in
blood during infection [111]. Although it appears to be a promising approach
for direct detection of spirochetes, PCR has not been widely accepted as a
laboratory diagnostic for Lyme disease due to low sensitivity in blood and
cerebral spinal fluid and accidental laboratory contamination of samples with
small quantities of target DNA that can lead to potential false-positive results
[117]. For these reasons, indirect detection of infection by serology using
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ELISA and western blot has remained the method of choice in clinical
settings. With inherent limitations to two-tier testing discussed above, there
exists the opportunity for improvements to current Lyme disease diagnostics.
Immuno-PCR
Technique Summary
Immuno-PCR (iPCR) as first described by Sano et al. in 1992 [118]
combines the capability for signal amplification afforded by PCR with the
flexibility of an ELISA based approach, which can result in overall
improvement of conventional antigen detection methodology. The basic
design of the assay depends on the analyte (antigen or antibody) being
measured. Early versions of the technique used gel electrophoresis to
measure the amount of PCR product generated. This not only limited the
range of quantification that could be used for immuno-PCR but was also
laborious, had low sensitivity and provided limited applicability for quantitative
measurement. With the incorporation of real-time PCR into the existing
protocol, the amount of reporter oligonucleotide could be quantified with high
sensitivity and accuracy over a wide concentration range providing concise
and consistent measurements of antigens within a sample [119]. It was also
through elimination of the post-PCR processing steps used for gel
electrophoresis that both the total assay time as well as overall risk of
laboratory contamination were significantly reduced [119].
Following development and optimization by researchers of the iPCR
protocol for sensitive and quantitative detection of proteins in samples, studies
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were undertaken to determine the sensitivity of the approach as compared to
standard ELISA protocols. Results indicated that typically 100-10,000-fold
detection limit improvements were observed in almost all applications [120].
iPCR has been applied for sensitive detection of a variety of targets including
viral antigens [121], bacterial antigens [122], prions [123] and bacterial toxins
[124]. There has been only a limited number of iPCR studies focused on host
generated antibody detection, with successful application to the measurement
of mumps-specific IgG in human patient serum [125].
Application of iPCR for Lyme Disease
Although two-tier testing based on ELISA followed by immunoblot is
the current accepted method of Lyme disease diagnosis, a better approach
would be to increase the sensitivity of the current system through
incorporation of PCR signal detection combined with the use of recombinant
antigens. The issues posed by the current approach including limited
sensitivity, subjectivity of analysis and inconsistency in capture antigens have
the potential to be alleviated through the application of iPCR and recombinant
B. burgdorferi in vivo-expressed antigens. An iPCR-based assay design for
indirect detection first requires antigens specific for host generated antibodies
to be immobilized to a surface, which can include a microtiter plate, magnetic
beads or any suitable vessel. The patient sample is then exposed to the
antigen-coated surface and any antibodies present in the sample will bind the
antigens immobilized on the surface. A secondary reporter antibody coupled
to a DNA oligonucleotide is then added and binds to any human antibodies
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that were captured by the surface bound antigens. The DNA reporter
oligonucleotide attached to the secondary antibody is then amplified by PCR
following extensive washing of the complex to remove any unbound reagents.
By determining the cycle number where the exponential phase of amplification
is achieved during PCR, the amount of antibody present in the patient sample
can be quantitatively determined. iPCR has already demonstrated increased
sensitivity for other applications and use of recombinant antigens could
provide both standardized reagents as well as provide a potential to combine
antigens from multiple species and strains in unique configurations [126].
Beyond just sensitivity, the multiplex capabilities, objective analysis and easeof-use of iPCR [127] make it a strong candidate for development of a new
Lyme disease diagnostic. The workflow for iPCR could also be further
simplified and automated by transfer to automated systems and even
microfluidic point-of-care diagnostic platforms as has been accomplished for
similar protocols [128]. Reduction in the assay complexity would provide the
capability for more routine, affordable and high-throughput diagnostic testing
of Lyme disease patients.
The overall goals of the research detailed in this dissertation were to 1)
develop an iPCR protocol suitable for detection of a B. burgdorferi infection, 2)
apply the protocol using in vitro expressed recombinant antigens for direct
detection of spirochetes and indirect detection of host generated antibodies in
an infected murine model and 3) determine the level of sensitivity and
specificity of the optimized protocol with more comprehensive testing of
human Lyme disease patient and healthy donor samples.
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CHAPTER TWO:
ENHANCED DETECTION OF HOST RESPONSE ANTIBODIES TO
BORRELIA BURGDORFERI USING IMMUNO-PCR

Preface
The first complete draft of the chapter was written by MDH. Comments
from MWJ and reviewers were incorporated into the final version presented
here. This chapter was published previously and is reprinted here with
permission. Copyright © American Society for Microbiology, Halpern MD,
Jain S, Jewett MW. 2013. Enhanced detection of host response antibodies to
Borrelia burgdorferi using immuno-PCR. Clin Vaccine Immunol. 20(3):350.
DOI: 10.1128/CVI.00630-12.
Introduction
Lyme disease is the leading vector-borne bacterial disease in the world
with approximately 30,000 cases reported in the United States alone each
year [37]. Lyme disease has been characterized as the fastest growing
zoonotic disease in North America. According to the Centers for Disease
Control and Prevention (CDC), the number of clinical cases of Lyme disease
has more than doubled over the past 10 years making this emerging
infectious disease a major public health concern [37]. Accurate diagnosis is
currently the greatest challenge for the clinical management of Lyme disease.
Misdiagnosis is common as the clinical manifestations of the disease are not
unique and detection of a B. burgdorferi infection is difficult and prone to
misinterpretation [111, 129]. Different approaches for laboratory testing, such
as microscopy, genomic DNA amplification and serology have been examined
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with currently accepted laboratory diagnostics relying primarily on detection of
a serological response to B. burgdorferi antigens [111, 130, 131].
Current methods for detection of Lyme disease in a clinical setting as
approved by the CDC entail a two-tiered approach using a first tier enzyme
immunoassay (EIA) followed by a second tier immunoblot for both IgM and
IgG B. burgdorferi specific antibodies using whole cell B. burgdorferi lysates,
recombinant antigens or various combinations depending on the commercial
kit used [111]. Although adequate, the approach suffers from certain
drawbacks including the subjectivity of immunoblot analysis and the lack of
standardization of antigen source and lysate preparations. These challenges
have resulted in discordant results between test strategies for detection of
host antibodies based on the kit used [112] largely due to lysate/antigen
reagent variability [111]. The most effective approach appears to be the use of
a combination of recombinant antigens to replace whole organism sonicates
as no single antigen has been found to be sufficient for accurate diagnosis
[111].
Other methods for detection of Lyme disease include live culture and
approaches employing polymerase chain reaction (PCR). Live culture has
shown limited success in a clinical setting, is time consuming and requires
complex media that have a limited commercial supply [111]. PCR appears to
be the most promising method for direct detection of spirochetes but has not
been widely accepted for laboratory diagnosis due to low sensitivity in
cerebral spinal fluid and blood and the potential false-positive results due to
accidental laboratory contamination of samples with small quantities of target
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DNA [117]. An improved approach would be to utilize the sensitivity of PCR
combined with an antigen based detection system that is much less
susceptible to false positive results.
Immuno-PCR (iPCR) was first introduced by Sano et al. in 1992 [118]
and combines the amplification power of PCR with the versatility of EIA
resulting in improved conventional antigen detection sensitivity. Using iPCR, a
typical 100-10,000-fold improvement over the detection limit of the EIA has
been obtained in almost all applications [120]. iPCR has been used to detect
viral antigens [121], bacterial antigens [122], prions [123] and bacterial toxins
[124]. There has also been a limited application of iPCR for antibody
detection, such as the measurement of mumps-specific immunoglobulin G in
human serum [125].
The combination of an iPCR approach and recombinant B. burgdorferi
in vivo-expressed antigens has the potential to alleviate a number of the
issues posed by Lyme disease diagnostics. Recombinant antigens not only
have the potential to standardize the reagents used for Lyme disease
diagnostics but also provide the opportunity to combine antigens from multiple
strains/species. The sensitivity, ease-of-use, objective analysis and multiplex
capabilities of iPCR [127] also makes it an ideal platform for Lyme disease
detection. Furthermore, iPCR has the ability to be translated to an automated
point-of-care diagnostic platform using microfluidics [128] that may allow
routine, high-throughput and affordable diagnostic testing of Lyme disease
patients. The goal of this research was to explore the initial application of
iPCR using recombinant antigens for detection of either host generated
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antibodies or direct detection of spirochetes in B. burgdorferi infected
samples.

Materials and Methods
Bacterial Strains
B. burgdorferi clone B31 A3 [132] and B31 A34/pBSV2G-loxP-flaBpgfp [133] were used in these studies. Spirochetes were grown in liquid
Barbour-Stoenner-Kelly (BSK) II medium supplemented with gelatin and 6%
rabbit serum [134] and plated in solid BSK medium as previously described
[135]. All spirochete cultures were grown at 35C and supplemented with
2.5% CO2. Gentamicin was used at 40 g/ml. Escherichia coli strains DH5α
and BL21 (Novagen, Billerica, MA) were grown in LB broth, on LB agar plates
or in Magic Media (Invitrogen, Carlsbad, CA) containing 100 g/ml ampicillin.
Mouse Infections
The University of Central Florida (UCF) is accredited by the
International Association of Assessment and Accreditation of Laboratory
Animal Care. Protocols for all animal experiments were prepared according to
the guidelines of the National Institutes of Health and approved by UCF’s
Institutional Animal Care and Use Committee. For the serological detection
experiments, the hair on the upper backs of three mice (C3H/HeN, 6- to 8week old females; Harlan Laboratories, Inc, Dublin, VA) was removed by
shaving and the mice were needle inoculated intradermally on the upper back
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with B. burgdorferi strain B31 A3 at a dose of 1x105 spirochetes divided
between two 50 l inoculations. The number of spirochetes inoculated into
mice was determined using a Petroff-Hausser counting chamber and verified
by colony forming units (cfu) counts in solid BSK medium. Total plasmid
content of each inoculum was confirmed to be as expected [136]. Whole
blood samples were collected from the three inoculated mice as well as one
non-inoculated mouse by submandibular bleed pre-inoculation and at days 1,
3, 4, 7, 9, 11, 14, 16, 18 and 21 post-infection. The coagulated blood was
spun at 4,000xg for 9 minutes to prepare serum. For the spirochete detection
experiments, six mice (C3H/HeN, 6-8 week old females, Harlan Laboratories,
Inc, Dublin, VA) were inoculated intradermally with B. burgdorferi strain B31
A3 at a dose of 1x105 spirochetes. Approximately 50 l of blood were
collected by submandibular bleed from all mice prior to inoculation.
Subsequently, to prevent complications due to oversampling, approximately
50 l of blood/mouse were collected every day from groups of two mice so
that each group of two mice was bled every three days over a time period of
14 days. All blood samples (pre- and post-inoculation) were supplemented
with an equal volume of 0.5M sodium EDTA to prevent coagulation.
Similar to plating of in vitro grown B. burgdorferi, 50 l of blood from each
mouse was combined with BSK plating medium [135] supplemented with a
Borrelia antibiotic cocktail consisting of 20 l /ml phosphomycin (MP
Biomedicals, Santa Ana, CA), 50 l /ml rifampicin (Fisher Scientific, Waltham,
MA ) and 2.5 l /ml amphotericin B (Fisher Scientific, Waltham, MA ), all
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solubilized in 20% DMSO, poured into sterile petri plates, allowed to solidify
and incubated as indicated above for approximately 7 days until B. burgdorferi
colonies were visible in the solid medium.
Immunoblot and C6 ELISA
Total B. burgdorferi lysate for immunoblot analysis was prepared from
a 500 ml culture of 1x108/ml B. burgdorferi B31 A3. Spirochetes were
harvested by centrifugation and washed two times in 30 ml phosphate
buffered saline, pH 7.4 (PBS). Washed cells were resuspended in 30 ml PBS
and disrupted by sonication on ice using a Misonix model S-4000 sonciator at
40% amplitude for four repetitions at 20 seconds each. Total protein in the
sonicate was normalized to 1 mg/ml with PBS based on absorbance at 280
nm and 75 g of protein were separated by 12.5% polyacrylamide gel
electrophoresis. Following protein transfer, nitrocellulose membranes were
incubated for 1 hour with pre- and post- inoculation mouse sera diluted 1:200
in Tris buffered saline/0.05% tween, pH 7.6 (TBST), washed twice with TBST,
incubated with HRP-conjugated goat anti-mouse IgG/IgM (Chemicon
International, Billerica, MA) for 1 hour, washed twice with TBST and the signal
was detected using the SuperSignal West Pico Chemiluminescent Substrate
Kit (Thermo Scientific, Rockford, IL). The C6 B. burgdorferi ELISA was
performed according to manufacturer’s protocol (Immunetics, Boston, MA)
with the exception of the use of HRP-conjugated goat anti-mouse IgG/IgM
secondary (Chemicon International, Billerica, MA) at a 1:5000 dilution in place
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of the anti-human reporter antibody provided with the kit when mouse sera
were analyzed.
Cloning and Expression of Recombinant GST Tagged Antigens
In frame glutathione-S-transferase (GST) fusion proteins for OspC,
BmpA and the VlsE C6 peptide were generated by PCR amplifying the
corresponding coding regions without the signal sequences from B.
burgdorferi genomic DNA using primer pairs P1 and P2 (OspC), P3 and P4
(BmpA) or P5 and P6 (VlsE C6) engineered with BamHI or SalI restriction
sites (Table 1) and Phusion polymerase (New England Biolabs, Ipswich, MA).
PCR products were purified (Qiagen, Valencia, CA), digested with restriction
enzymes (New England Biolabs, Ipswich, MA) and cloned into BamHI/SalIdigested pGEX-6P-1 (GE Healthcare, Piscataway, NJ) to generate
translational fusions with GST at the N-terminus. Subsequent clones were
selected and sequence confirmed by dideoxy sequencing. Hemagglutinin
(OspC) and C-Myc (BmpA) tags were included at the C-terminus for
determination of protein purity by immunoblot. pGEX-6P-1 plasmids carrying
ospC, bmpA or vlsE c6 were transformed into a BL21 strain of E. coli
(Novagen, Billerica, MA). Protein expression and purification were performed
according to the procedures outlined in the Bulk GST Purification Module (GE
Health Sciences, Piscataway, NJ).
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Table 1. iPCR DNA oligonucleotide sequences used in this study
Oligo
number

Sequence (5’-3’)a

Oligo ID

T1

Template 1 (IgG coupled)

BIOTIN-agcctcagaccaagccagacaactgcctcgtgacgttgctgcccctaccaacgtacccctacgagtcc

T1F

Template 1 Forward

agcctcagaccaagccagac

T1R

Template 1 Reverse

ggactcgtaggggtacgttgg

T1P

Template 1 Probe

FAM-actgcctcgtgacgttgctgcccct-BHQ1

T2

Template 2 (IgM coupled)

BIOTIN-aggaggagggtcaagtcaccaacgctgctccaggccatcgtgctgatctggaccctggatcgagtga

T2F

Template 2 Forward

aggaggagggtcaagtcacc

T2R

Template 2 Reverse

tcactcgatccagggtccag

T2P

Template 2 Probe

MAX-acgctgctccaggccatcgtgctga-BHQ1

P1

OspC partial HA F

CGGGATCCCATATGtgtaataattcagggaaagatgg

P2

OspC HA R

ACGCGTCGACttaCGCATAATCCGGCACATCATACGGATAaggtttttttggactttctgc

P3

BmpA partial myc F

CGGGATCCCATatgtgtagtggtaaaggtagtcttg

P4

BmpA myc R

ACGCGTCGACttaCAGATCTTCTTCAGAAATAAGTTTTTGTTCaataaattctttaagaaacttctcataac

P5

C6 Bb F

CGGGATCCCATatgaagaaggatgatcagattg

P6

C6 Bb R

ACGCGTCGACttacttcacagcaaactttccatc

a

Uppercase letters indicate non-template sequence used for addition of terminal restriction sites and/or epitope tags. BHQ1,
black hole quencher 1.
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iPCR Reagent Preparation
iPCR assays were assembled as two-sided (sandwich) as detailed in
Figure 4 for both host antibody (A and B) and spirochete capture (C). Whole
cell lysate used for immunoblot analysis (preparation described above) and
GST-fusion recombinant antigens were used to coat magnetic beads for host
antibody capture using Dynabeads Antibody Coupling Kit (Invitrogen,
Carlsbad, CA). Bead coupling reactions were performed overnight according
to the manufacturer’s protocol using 20-30 g antigen(s) per mg Dynabeads
M-270 Epoxy. The primary antibody used for spirochete capture consisted of
protein A purified anti-B. burgdorferi polyclonal antibody raised in rabbits
against whole cell preparations of B. burgdorferi clone B31 ATCC #35210
(Acris Antibodies, San Diego, CA) and was coupled to magnetic beads as
described above. Protein coated beads were stored at 4C. The streptavidin
conjugated reporter antibodies were prepared using the Lightning-Link
Streptavidin Conjugation Kit (Innova Biosciences, Cambridge, United
Kingdom) using polyclonal anti-B. burgdorferi (Acris Antibodies, San Diego,
CA), goat anti-mouse IgM/IgG (Sigma-Aldrich, St. Louis, MO), goat antihuman IgG (Invitrogen,
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Figure 4. Schematic representation of iPCR assay for detection of Lyme
disease biomarkers. (A) Intact spirochete or (B) recombinant protein antigen
coupled to magnetic beads was used to capture B. burgdorferi-specific host
generated antibodies. A biotinylated DNA oligonucleotide reporter molecule
coupled to a streptavidin conjugated reporter antibody was amplified by qPCR
for detection and quantification. (C) Anti-B. burgdorferi antibody coupled to
magnetic beads was used for spirochete capture with detection accomplished
by qPCR amplification of the DNA oligonucleotide coupled reporter antibody
similar to detection of host antibody.

Carlsbad, CA) or goat-anti-human IgM (Invitrogen, Carlsbad, CA)
according to manufacturer’s protocols using an overnight incubation.
Following conjugation, 10 l of streptavidin labeled antibody was diluted 1:50
in TBST and 100 nM of single stranded biotin-labeled oligonucleotide
template was added and the mixture rotated at room temperature for 30
minutes for antibody-oligo conjugation. Oligonucleotide sequences T1 (IgG
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coupled) and T2 (IgM coupled) used for tagging are listed in Table 1. The
oligonucleotide linked streptavidin conjugated antibody was then diluted to a
1:100 working stock (1:5000 final dilution) and stored at 4C.
iPCR assay
Following reagent preparation, 10 l of antigen or antibody coated
magnetic beads were incubated in 500 l TBST for 30 minutes at 25C on a
rotator. Following preliminary washing, beads were resuspended in 500 l
TBST and 5 l serum (mouse or human), 10 l spirochetes suspended in HN
buffer or blood (1x108-1x104/ml B. burgdorferi B31 A3) or no serum/spirochete
(negative control) and incubated at 25C rotating for 30 minutes. Beads were
subsequently washed and resuspended in 300 l TBST with the addition of
100 l each of IgG and IgM diluted (1:5000) biotinylated oligonucleotide
streptavidin coupled reporter antibody (anti-mouse IgM/IgG, anti-human IgG,
anti-human IgM or anti-B. burgdorferi) and incubated at 25C rotating for 30
minutes. Following assembly of the immune complex, beads were washed
three times with 900 l TBST followed by magnetic bead capture. Washed
immune complex coupled beads were resuspended in 20 l TBST for
subsequent PCR amplification.
Signal Amplification by Real-Time PCR
To amplify the signal of the immune complex, real-time PCR was
performed using an Applied Biosystems 7900 HT (Life Technologies, Grand
Island, NY) and IQ Supermix (Bio-Rad, Hercules, CA) supplemented with
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synthetic primers and probes T1F/T1R/T1P (IgG detection) or T2F/T2R/T2P
(IgM detection) (Table 1). Duplicate reactions were prepared in 20 l volumes
containing 5 l of iPCR assay processed beads as template, 10 l of 2X
reaction mix, 0.2 M each primer and 0.4 M fluorophore labeled probe.
Cycle parameters included a preliminary denaturation (95°C, 20 sec), followed
by 40 cycles of denaturation (95°C, 1 sec) and annealing/extension (60°C, 20
sec). The fluorescent signal was collected at the FAM wavelength for IgG
reactions and MAX wavelength for IgM reactions. The quantification cycle
(Cq) for each reaction was determined using automatic baseline and
threshold settings. The average and standard deviation for uninfected/healthy
samples were used to determine the background level of amplification as is
commonly observed for iPCR protocols. Positive threshold values were
established at three times the standard deviation for background levels.
Human Sera
Retrospective, de-identified human Lyme disease and healthy control
serum samples were kindly supplied by Dr. Martin Schriefer (Centers for
Disease Control and Prevention, Fort Collins, CO). Patient sera were
collected from 18 Lyme disease patients from endemic Lyme disease regions
upon initial visit to a physician and 10 days post-initial visit (n = 36). According
to the CDC’s 2-tiered serological analysis of the samples, 5 of the patients
were 2-tiered positive at both the initial and follow-up time points, 3 of the
patients were 2-tiered negative a both time points and 10 of the patients were
2-tiered negative at the initial visit but 2-tiered positive 10 days later. Human
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control samples consisted of sera collected from healthy blood donors living in
non-Lyme endemic areas (n = 5).
Statistical Analysis
Spearman rank correlation analyses were performed using GraphPad
Prism, version 5.0.
Results
iPCR Using Intact Spirochetes Provided Earlier Detection of Host Response
Compared to Immunoblot and C6 ELISA in a Murine Model
The general approach for detection of a host antibody immune
response by immunoassay is to use sonicated or otherwise disrupted
organisms to generate protein antigens for antibody capture and subsequent
detection. However, we hypothesized that this approach may have limited
success for effectively capturing anti-B. burgdorferi antibodies in
experimentally infected mouse sera as the majority of the B. burgdorferi
proteins in the total cell lysate are not likely to be immunogenic. Although B.
burgdorferi lysate is known to harbor antigenic proteins recognized by mouse
and human immune sera, these proteins represent a small percentage of the
total proteins in the lysate and therefore may not provide improved sensitivity
of detection of an immune response to B. burgdorferi infection. In an effort to
develop a sensitive, objective method for detection of host antibodies against
B. burgdorferi antigens, magnetic beads were coated with a polyclonal anti-B.
burgdorferi Antibody in order to capture formalin fixed intact spirochetes,
resulting in the generation of magnetic beads coated with intact spirochetes
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(Figure 5). We predicted that this strategy would result in magnetic beads
coated in an enriched pool of spirochete antigenic outer surface proteins
capable of interacting specifically with host antibodies produced in response
to a B. burgdorferi infection. The sensitivity of iPCR using intact spirochetes to
capture host antibodies was compared to pre-existing diagnostic methods
including a commercial C6 ELISA and immunoblot using an in vivo murine
model. iPCR resulted in the earliest objective detection of a positive infection
on day 11 post-inoculation (Figure 6A). In comparison, C6 ELISA and
immunoblot exhibited positive detection of anti-B. burgdorferi antibodies at
day 14 and day 21 post-inoculation, respectively (Figure 6B and 6C). The
approximate molecular weights of the immunodominant proteins detected on
the immunoblot included 18 kilodaltons (kDa), 23 kDa, 33 kDa, 39 kDa and 66
kDa, which are consistent with the sizes of the bands typically present on a
Lyme disease diagnostic immunoblot [99, 110]. Uninfected mouse serum was
negative by all three methods at all time points tested (Figure 6).
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Figure 5. B. burgdorferi captured on magnetic beads provides a reagent for
host antibody detection by iPCR. Phase contrast and fluorescent microscopy
at 510 nm (GFP) and 400x magnification (400x) was used to determine
capture of formalin fixed B. burgdorferi expressing green fluorescent protein
on beads coated with anti-B. burgdorferi polyclonal antibodies (top panels) or
uncoated beads (bottom panels).
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Figure 6. iPCR demonstrated earlier detection of host response antibodies in
B. burgdorferi infected mice compared to C6 ELISA and immunoblot. Mouse
sera were collected prior to inoculation (pre), at specific days post-intradermal
inoculation with 1x105 B. burgdorferi B31 A3 (left panels), or from uninfected
mice (right panels) over the course of 21 days. (A) Undiluted sera were
analyzed for detection of B. burgdorferi IgG antibodies using iPCR. Closed
system, real time PCR of the DNA reporter molecule was performed using a
Taqman-based fluorescent probe assay. The mean quantification cycle (Cq)
background signal, determined using uninfected sera plus three standard
deviations was designated as the call threshold for a positive detection event
and indicated here as ∆Cq = 0. Data are shown as the Cq value for each
sample minus the mean background Cq plus three standard deviations (∆Cq).
Each data point represents the average of three mice and the standard
deviation between samples is shown. (B) C6 ELISA (Immunetics, Inc.,
Boston, MA) was performed according to the manufacturer’s instructions with
the exception that the secondary antibody was peroxidase-conjugated goat
anti-mouse IgM/IgG (1:5000). The threshold absorbance for the test is
indicated (horizontal broken line). Each point represents the average of three
mice and the standard deviation between samples is shown. (C) Total B.
burgdorferi sonicate was separated by SDS-PAGE and analyzed by IgM/IgG
immunoblot using immune and pre-immune mouse sera diluted 1:200. The
positions of the protein standards depict molecular weights in kilodaltons
(kDa). Data are representative of three mice analyzed.
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iPCR Using Recombinant GST-OspC and GST-BmpA Provided
Improved Sensitivity of Detection of Murine Host Antibodies
Although beads coated with intact in vitro grown spirochetes provided
early detection of anti-B. burgdorferi antibodies as compared to the C6 ELISA
and immunoblot (Figure 6), we hypothesized that specific recombinant
antigens known to be actively expressed during murine infection could
potentially result in a more sensitive approach. Known B. burgdorferi in vivoexpressed antigens OspC and BmpA [111] were produced and purified as
recombinant N-terminal GST-tagged fusion proteins in E. coli. Magnetic beads
coated with either recombinant protein were used to capture host antibodies
generated against OspC or BmpA, respectively, and IgM and IgG antibodies
against each protein were individually quantitated using our iPCR assay.
GST-OspC coated beads resulted in a marked increase in detection of host
antibodies starting at day 7 post inoculation for both IgG and IgM (Figure 7A)
with a gradual decrease in IgM back to baseline by day 21 and a minimal
decrease in IgG signal to the same time point. GST-OspC-coated beads
provided a dramatic increase in the level of IgG detection (Cq = 10) as
compared to the level of iPCR detection of host antibodies using intact
spirochete-coated beads (Cq = 2.5). GST-BmpA-coated beads provided
robust positive detection of IgG antibodies beginning at day 9 followed by a
minimal decrease in the detection signal out to day 21 (Figure 7B). IgM
antibodies directed against BmpA demonstrated a slight increase in signal
over the 21-day time course of infection but were not significantly detected
above background, suggesting that BmpA does not elicit a serodiagnostic IgM
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response. Together these data suggest that the use of magnetic beads
coated with specific recombinant B. burgdorferi in vivo-expressed antigens
results in robust iPCR detection of a humoral response in mice experimentally
infected with B. burgdorferi and development of an iPCR assay that
quantitates the host response to multiple B. burgdorferi antigens may result in
an improved diagnostic method.
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Figure 7. iPCR using recombinant antigens OspC and BmpA provided
enhanced detection sensitivity for both IgG and IgM isotypes in a murine
model of infection. Magnetic beads coated with either purified recombinant
GST-OspC (A) or GST-BmpA (B) protein were used to capture host response
antibodies from pre-immune (pre) or post-immune mouse sera collected over
a time period of 21 days. IgM- and IgG-specific reporter antibody-DNA
conjugates detected anti-B. burgdorferi antibodies captured by each set of
antigen coated beads. The IgM (gray bars) and IgG (white bars) response to
each antigen was determined for each mouse by multiplex quantitative PCR
using distinct probes specific for the IgM- and IgG-specific DNA reporters
molecules. The mean quantification cycle (Cq) background signal, determined
using uninfected sera plus three standard deviations was designated as the
call threshold for a positive detection event and indicated here as ∆Cq = 0.
Data are shown as the Cq value for each sample minus the mean background
Cq plus three standard deviations (∆Cq). Each data point represents the
average of two mice and the standard deviation between samples is shown.
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iPCR Demonstrated a Strong Correlation with a Commercial ELISA for
Detection of Host Antibodies in Human Serum Using the VlsE C6 Peptide
As recommended by the CDC, the first step of two-tier testing for Lyme
disease is the use of a sensitive enzyme immunoassay. Although a number of
commercial kits exist for testing, the C6 peptide of the VlsE locus has been
shown to be a sensitive and effective predictor for follow-up testing by
immunoblot and is available as a commercial testing kit. In order to directly
compare the ability of our iPCR assay to detect human antibodies produced
against the VlsE C6 peptide with that of an FDA-approved C6 antibody
detection method, a panel of human serum samples that consisted of samples
from 18 individuals collected at both an initial visit to the clinic and a ten day
follow up appointment (n = 36) along with sera collected from 5 healthy
patients from non-Lyme endemic areas were analyzed by iPCR and using the
C6 Lyme ELISA (Immunetics, Inc., Boston, MA). iPCR detection of C6specific host antibodies demonstrated a strong correlation with that of the
commercial C6 ELISA (rs = 0. 895, P < 0.0001) (Figure 8). The iPCR assay
differed from the C6 ELISA in that the iPCR assay provided a separate
measurement of C6 IgM and C6 IgG antibodies as opposed to the C6 ELISA,
which quantitated a combined value for both C6 IgM and C6 IgG antibodies.
Therefore, the iPCR result was considered positive if C6 IgM and/or C6 IgG
antibodies were detected at or above the established call threshold. All 21
samples that demonstrated a positive result by the C6 ELISA were also
positive according to C6 iPCR (Figure 8). Of the four samples determined to
be equivocal by the C6 ELISA, three of the sera were found to be negative by
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C6 iPCR; whereas, one sample tested positive for IgM using this method.
Furthermore, of the 11 serum samples that tested negative by C6 ELISA, five
of those sera resulted in positive detection of IgM by C6 iPCR. Of note, all
iPCR positive samples in this group had ∆Cq values of 1 or below. All serum
samples collected from known healthy individuals tested negative by both C6
ELISA and C6 iPCR. Together these results suggested that iPCR may have
improved ability to detect host antibodies to the VlsE C6 peptide compared to
a current commercial method.
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Figure 8. Recombinant antigen iPCR successfully quantified B. burgdorferi
VlsE C6 peptide antibodies in human serum samples. Results for 36 serum
samples from 18 Lyme disease patients collected upon initial visit to a clinic
and at a 10 day follow up visit and 5 healthy controls using a multiplex iPCR
protocol to quantitate both IgM (gray bars) and IgG (white bars) isotypes using
recombinant B. burgdorferi VlsE C6 peptide coated magnetic beads. A call
threshold (∆Cq = 0) was assigned at greater than or equal to three standard
deviations above the mean background signal determined using serum from
healthy individuals. Serum samples were also tested using a commercial C6
ELISA (Immunetics, Boston, MA) (diamonds), which was performed according
to manufacturer protocol with a call threshold for an absorbance (450 nm) of
1.1 used according to the manufacturer’s protocol. The C6 ELISA value
represents combined measurement of C6 IgM and IgG antibodies. The patient
data (1-36) are grouped into three categories: positive, equivocal (equiv) and
negative according to the C6 ELISA values. Samples H1-H5 correspond to
the sera collected from the healthy controls and are grouped accordingly
(healthy). The calculated Spearman rank correlation (rs) was 0.734 (P <
0.0001) for C6 iPCR IgM versus C6, 0.826 (P < 0.0001) for C6 iPCR IgG
versus C6, and 0.895 (P < 0.0001) for C6 iPCR IgM and/or IgG versus C6.
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iPCR Directly Detected B. burgdorferi in Blood
The demonstrated power of iPCR to detect ultra-low protein levels
[120] suggests that this method may be a promising tool for direct detection of
B. burgdorferi in clinical samples. iPCR was shown to be successful for
capture of live B. burgdorferi using magnetic beads coated with polyclonal
anti-B. burgdorferi antibodies (Figure 5). This finding suggested the potential
for iPCR to directly quantitate spirochetes from within patient samples. To test
the sensitivity of iPCR detection of spirochetes, in vitro grown B. burgdorferi
were serially diluted in HN buffer (106-102 spirochetes). iPCR detection of
spirochetes demonstrated a robust dilution curve and a level of detection of
less than 1,000 organisms (Figure 9A). Detection of in vitro grown B.
burgdorferi spiked into whole uninfected mouse blood resulted in a ten-fold
lower limit of detection of 10,000 spirochetes (data not shown), suggesting
that components of the blood may have an inhibitory effect on the function of
the iPCR assay. To correlate the sensitivity of iPCR detection of spirochetes
in blood with quantitation of the number of spirochetes present in the blood of
infected mice, cohorts of mice were infected with 1x105 B. burgdorferi B31 A3
and blood samples collected every 24 hours for a period of fourteen days. The
number of spirochetes/ml of blood, as determined by cfu counts on solid
medium, were found to increase over the first week of infection and reached a
peak number of approximately 2,500 spirochetes/ml of blood on day 8 postinoculation (Figure 9B). The B. burgdorferi colonies that grew out of the
infected blood within the solid BSK medium demonstrated morphology and
growth pattern similar to what is typically observed for spirochete colonies
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derived from in vitro grown cultures (data not shown). Together, these data
suggest that although iPCR is a promising method for direct detection of
spirochetes in B. burgdorferi infected samples, the sensitivity of the method is
currently below the required level of detection.

Figure 9. iPCR has the potential to directly detect B. burgdorferi in infected
samples. (A) Live spirochetes were serially diluted in HN buffer (106-102
spirochetes) and tested in triplicate using iPCR to detect organism capture
using anti-B. burgdorferi antibody coated magnetic beads. A call threshold
was assigned at greater than or equal to five times the standard deviation (Cq
= 30, vertical broken line) above the mean background signal, as determined
using HN buffer alone (unspiked). PCR non-template controls (NTCs)
included water and TBST used during the iPCR protocol. (B) Six mice were
prebled (pre) and inoculated intradermally with 1x105 B. burgdorferi strain B31
A3. Approximately 50 µl of blood/mouse was collected every day from groups
of two mice every three days over a time period of 14 days. Blood collected
from each mouse was plated in solid medium using 50 µl of blood and
supplemented with a Borrelia antibiotic cocktail (see Materials and Methods
for details) and the number of colony forming units (cfus) per ml of blood
determined. Data shown are the average cfus/ml for the two mice sampled at
each time point.
48

Discussion
There is a critical need for development of innovative methods for
improved diagnosis of Lyme disease. Because of its immunological specificity,
signal amplification power and potential for high-throughput automation, iPCR
is a strong candidate for development of a robust method to overcome the
challenges of Lyme diagnosis. We have demonstrated the first application of
iPCR for detection of host antibodies against B. burgdorferi in both a murine
model and human sera.
iPCR Using Recombinant B. Burgdorferi in Vivo-Expressed
Antigens Is a Sensitive Method for Detection of Host
Response Antibodies in Infected Mice
An iPCR assay that incorporated attachment of intact spirochetes to
magnetic beads provided approximately equivalent sensitivity to current
diagnostic methods including C6 ELISA and immunoblot when tested in a
murine model. However, it is well known that B. burgdorferi can alter its
surface protein expression based on its environment [137-139]. These data
have led to the conclusion that in vitro grown spirochetes likely do not present
equivalent amounts and types of surface proteins as would be encountered by
the host immune system in an active B. burgdorferi infection and suggest that
the use of multiple in vivo-expressed recombinant antigens may improve
assay sensitivity [140].
B. burgdorferi has been shown to express a number of antigens during
an active infection that can be utilized as recombinant antigens including
OspC [141], BmpA [142] to detect host antibodies against B. burgdorferi [99].
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We hypothesized that saturating the magnetic beads with recombinant in vivoexpressed antigenic proteins would provide more binding targets and hence
higher sensitivity than intact spirochetes. This was evident in the fact that
active infection was detected on day 7-9 post-inoculation using recombinant
antigen coated beads as compared to day 11 using intact spirochete coated
beads and with a stronger signal above background, ∆Cq =5-10 compared to
∆Cq = 2.5, respectively. This approach also provides the opportunity to utilize
multiple specific antigens either in a combined or individual assay that can be
objectively quantified by qPCR.
Recombinant Antigen iPCR Successfully Quantified B. burgdorferi
VlsE C6 Peptide Antibodies in Human Serum Samples
The immunodominant C6 peptide domain of the VlsE protein has
proven successful as a diagnostic antigen [143] and has become a popular
choice for first-tier testing prior to follow-up immunoblot testing [144]. An iPCR
assay employing a recombinant C6 peptide was developed and compared to
an existing commercial kit that uses the same antigen. iPCR detection of C6
antibodies in human sera demonstrated a strong correlation with that of the
commercial C6 Lyme ELISA. The C6 ELISA assay results in a combined
score for detection of both IgG and IgM isotypes. To provide an additional
level of discrimination, the iPCR protocol separately quantitates IgG and IgM
antibodies using distinct qPCR template tags and fluorophores, resulting in an
individual IgG and IgM iPCR score for each serum sample. All C6 ELISA
positive sera were found to be positive for IgG and/or IgM C6 antibodies by
iPCR. The added ability of the iPCR assay to differentially quantitate antibody
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isotypes for a specific antigen of interest in a single sample may provide
important information regarding the disease stage at the time of testing, as
IgM is typically produced early in infection with IgG produced later and for
longer durations [99, 109].
Of the serum samples that were found to be equivocal or negative by
C6 ELISA, a subset of samples in each category was found to be positive by
the C6 iPCR assay. These results imply that the iPCR assay may have
increased sensitivity of detection over the C6 ELISA; however, further
analysis of a larger serum panel is required to fully support this finding. Serum
samples from “healthy” individuals with no known exposure to B. burgdorferi
tested negative by both C6 ELISA and iPCR, suggesting equivalent specificity
for the two methods. However, considering the small sample size (n = 5),
additional samples need to be tested to confirm this result.
iPCR Has the Potential for Direct Detection
of Spirochetes in Infected Samples
In an effort to test applicability of iPCR for direct detection of
spirochetes within a sample, it was determined that 1,000 spirochetes were
needed in buffer and 10,000 organisms where needed in blood. In the murine
model used for development of the protocol, the maximum spirochete load in
blood was measured to be approximately 2,500 spirochetes/ml. Therefore the
current protocol is unable to directly detect spirochetes during an active
murine infection. It has been estimated that the average number of cultivable
B. burgdorferi cells per ml of whole blood in humans is approximately 0.1
spirochetes per ml and therefore re-isolation of spirochetes from blood has
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demonstrated limited efficacy when using small volumes of blood [145].
Hence, an alternative approach has been proposed to sample blood cultures
and test by qPCR for increasing amounts of spirochete DNA [146]. While an
enrichment step is practical, the use of qPCR has the potential to introduce
false positive results from contaminating B. burgdorferi template DNA in the
laboratory and typically requires additional protocol steps for nucleic acid
purification. iPCR, which herein has demonstrated successful detection of
spirochetes directly from whole blood and is much less prone to the same
contamination issues as the PCR template is unrelated to B. burgdorferi and
human DNA, could effectively be used to make a more rapid diagnosis from
B. burgdorferi infected blood cultures. Future work will focus on improving the
limit of iPCR direct detection of spirochetes in blood to achieve a detection
sensitivity of 1-10 organisms, as has been demonstrated for other microbial
pathogens [122, 147-149]. Furthermore, as B. burgdorferi is transiently
present in the blood of infected patients the iPCR method may also be
adapted for direct detection of spirochetes in synovial fluid and/or cerebral
spinal fluid. Direct detection of spirochetes in patient samples is not
anticipated to serve as the sole method for diagnosis of Lyme disease, rather
in conjunction with sensitive and specific detection of B. burgdorferi
antibodies.
Contributions of an iPCR-Based Approach Using Recombinant
Antigens to Future Automated Lyme Disease Diagnostics
The field of Lyme disease diagnostics is challenged by two main
issues, a lack of consistent reagents and the need for a more simplified
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objective form of testing [111]. There are currently multiple commercial assays
that use a range of antigen types from single recombinant antigens to multiple
antigens to whole sonicated organisms. One principal focus for the field has
been on the use of purified, recombinant, or synthetic peptides as the source
of antigens in immunoassays [111]. Unfortunately, no single antigen has
demonstrated sufficient sensitivity and specificity to warrant replacing two-tier
testing [111]. Protein expression differences among species and temporal
appearance of relevant antibodies to different antigens at various stages of
Lyme disease make the choice of a single antigen a difficult task and makes
the combined use of antigens an attractive alternative [111]. The results
presented here suggest that iPCR combined with the use of recombinant B.
burgdorferi in vivo-expressed antigens has the potential to provide improved
sensitivity of detection in an objective format that can be used to detect
multiple host response antibodies and isotypes. Moreover, future translation
of this method to an automated point-of-care platform will allow for objective
routine testing of Lyme disease patients.

53

CHAPTER THREE:
SIMPLE QUANTITATIVE DETECTION OF HUMAN LYME DISEASE
INFECTION USING IMMUNO-PCR DETECTION OF
HOST GENERATED IgG ANTIBODIES AGAINST
A SINGLE HYBRID RECOMBINANT ANTIGEN

Introduction
Lyme disease is the most commonly reported tick-borne illness in the
United States with approximately 30,000 cases reported to the Centers for
Disease Control and Prevention (CDC) each year [12]. New preliminary
estimates released by the CDC indicate that the number of Americans
diagnosed with Lyme disease each year is closer to 300,000, which are
roughly 10 times higher than the annual number reported [13]. This new
estimate supports studies published in the 1990s indicating that the true
number of cases is between 3- and 12-fold higher than the number of
reported cases [150, 151] making Lyme disease a significant health concern
within the United States. Accurate diagnosis provides a significant obstacle
for the clinical management of the disease and is necessary to differentiate
Lyme disease from other diseases with similar clinical presentation.
Misdiagnosis of Lyme disease is common due to difficulties in detection of
Borrelia burgdorferi, the causative agent of Lyme disease [152]. Although a
wide range of laboratory diagnostic approaches have been explored, the
current accepted method utilizes detection of serological response to B.
burgdorferi antigens [114].
The current method for detection of Lyme disease in a clinical setting
approved by the CDC entails a two-tiered approach using a first-tier enzyme
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immunoassay (ELISA) followed by a second-tier immunoblot assay for both
IgM and IgG B. burgdorferi-specific antibodies using whole cell B. burgdorferi
lysates, recombinant antigens, or various combinations depending on the
commercial kit used [111]. The ELISA provides a quantitative and sensitive
first-tier screen but lacks the specificity and broad strain applicability [153]
required for a standalone test. The second-tier immunoblot provides a higher
level of specificity but currently requires somewhat subjective analysis due to
its qualitative nature and lack of automation [154]. A tiered approach has to
date provided the most effective means of diagnosing Lyme disease in a
clinical setting [111].
Other approaches to diagnosing Lyme disease have been developed
including live culture, PCR and additional molecular based methods with no
technique surpassing the effectiveness of a serology based approach [111].
In our previous study we demonstrated the use of immuno-PCR (iPCR) for
detection of host generated antibodies in a murine model as well as
preliminary data using serum collected from Lyme disease patients and
healthy controls [155]. Our results indicated that iPCR using B. burgdorferi
whole cell sonicates and a limited number of B. burgdorferi recombinant
antigens provided higher sensitivity of detection of B. burgdorferi antibodies in
infected mice and equivalent sensitivity of detection of B. burgdorferi
antibodies in Lyme patient serum compared to both ELISA and immunoblot
[155].
It is well established that multiple antigens are required for accurate
overall diagnosis of the multiple stages and types of Lyme disease [111].
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Furthermore, it is critical that the antigens used for diagnosis are
demonstrated to have low cross-reactivity for diseases other than Lyme
disease. The goals of this study were to 1) determine the range of the levels
of background detection of the Lyme disease iPCR assay across a healthy
human population, 2) explore a larger subset of antigens for increased
sensitivity and specificity and 3) compare the performance of the optimized
Lyme disease iPCR protocol with the current 2-tier method of Lyme disease
diagnosis.
Materials and Methods
Healthy Human Sera
The current study was approved by University of Central Florida’s
Institutional Review Board (UCF IRB; FWA00000351, IRB00001138). All
procedures and investigators involved in the sample collection process were
UCF IRB-approved with Collaborative Institutional Training Initiative training.
All donors provided written consent to participate in the current study. Sample
collection was undertaken at the UCF campus. UCF is a diverse community
of nearly 60,000 students and approximately 8,000 faculty and staff members
of various ages, ethnic and racial backgrounds. Individuals were classified for
inclusion in the study if they had not been previously diagnosed with Lyme
disease, received a Lyme vaccine or lived within the past 10 years in a state
with a high incidence of Lyme disease (Connecticut, Delaware, Maine,
Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New
York, Pennsylvania, Vermont, Virginia and Wisconsin). Approximately 10
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millilitres of blood were sampled according to the IRB approved protocol from
36 individuals into serum separator tubes, inverted five times to mix the clot
activator with the blood and allowed to clot for at least 30 minutes. Serum
fractions were collected by centrifugation at 1200 x g for 10 minutes. Serum
was further clarified by centrifugation at 9100g for 5 minutes to remove any
insoluble material and stored at 4°C for short term or -80°C for long term
storage.
Lyme Disease Human Sera Panel
Retrospective, human Lyme disease and healthy control serum
samples were kindly supplied by Dr. Martin Schriefer (Centers for Disease
Control and Prevention, Fort Collins, CO). The CDC Research Panel I
consisted of patient sera collected from 32 individuals including patients with
stage 1, 2 or 3 Lyme disease (n=12), look-alike diseases including
fibromyalgia, rheumatoid arthritis, multiple sclerosis, mononucleosis, syphilis
and severe periodontitis (n=12) and healthy individuals from both Lyme
disease endemic (n=4) and non-endemic (n=4) areas. All Lyme disease
samples were confirmed B. burgdorferi culture and PCR positive. The blinded
CDC Research Panel II consisted of patient sera collected from 92 individuals
including patients with stage 1, 2,or 3 Lyme disease (n=32), look-alike
diseases including fibromyalgia, rheumatoid arthritis, multiple sclerosis,
mononucleosis, syphilis and severe periodontitis (n=36) and healthy
individuals from both Lyme disease endemic (n=12) and non-endemic (n=12)
areas. Similar to CDC Research Panel I, all Lyme disease samples in CDC
57

Research Panel II were confirmed B. burgdorferi culture and PCR positive.
Prior to analysis all serum samples were clarified by centrifugation at 9,100 x
g for 5 minutes to remove any insoluble material and stored at 4°C.
Cloning and Expression of Recombinant
Antigens Lacking GST Fusion Tags
rGST-BmpA and rGST-OspC were constructed as previously described
[155]. In frame glutathione-S-transferase (GST) fusion proteins for BBK19,
OspA, DbpA, RevA, Crasp-2 and BBK50 were generated by PCR amplifying
the corresponding coding regions without the signal sequences from B.
burgdorferi genomic DNA using primer pairs 1147 and 1148 (BBK19), 1151
and 1152 (OspA), 1145 and 1146 (DbpA), 1143 and 1144 (RevA), 1149 and
1150 (Crasp-2) or 1043 and 1044 (BBK50) engineered with BamHI and SalI
or XhoI restriction sites (Table 2) and Phusion polymerase (New England
Biolabs, Ipswich, MA). PCR products were purified (Qiagen, Valencia, CA),
digested with appropriate restriction enzymes (New England Biolabs, Ipswich,
MA) and cloned into BamHI and SalI or XhoI-digested pGEX-6P-1 (GE
Healthcare, Piscataway, NJ) to generate translational fusions with GST at the
N-terminus. Subsequent clones were selected and sequence confirmed by
sequence analysis. pGEX-6P-1 plasmids carrying bmpA, ospC, bbk19, ospA,
dbpA, revA, crasp-2 or bbk50 were transformed into a BL21 strain of E. coli
(Novagen, Billerica, MA).
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Table 2. iPCR DNA oligonucleotide sequences used in this study
Oligo
number
T1
T1F
T1R
T1P
T2
T2F
T2R
T2P
1147
1148
1151
1152
1145
1146
1143
1144
1149
1150
1043
1044

Oligo ID
Template 1 (IgG coupled)
Template 1 Forward
Template 1 Reverse
Template 1 Probe
Template 2 (IgM coupled)
Template 2 Forward
Template 2 Reverse
Template 2 Probe
BBK19 F
BBK19 R
OspA F
OspA R
DbpA F
DbpA R
RevA F
RevA R
Crasp2 F
Crasp2 R
BBK50 F
BBK50R

Sequence (5’-3’)
BIOTIN-agcctcagaccaagccagacaactgcctcgtgacgttgctgcccctaccaacgtacccctacgagtcc
agcctcagaccaagccagac
ggactcgtaggggtacgttgg
FAM-actgcctcgtgacgttgctgcccct-BHQ1
BIOTIN-aggaggagggtcaagtcaccaacgctgctccaggccatcgtgctgatctggaccctggatcgagtga
aggaggagggtcaagtcacc
tcactcgatccagggtccag
MAX-acgctgctccaggccatcgtgctga-BHQ1
CGGGATCCttttcaaaagattctcgatcacg
ACGCCTCGAGtcaattgttaggtttttcttttcc
CGGGATCCaagcaaaatgttagcagcc
ACGCCTCGAGttattttaaagcgtttttaatttcatcaag
CGGGATCCggactaacaggagcaacaa
ACGCCTCGAGttagttatttttgcatttttcatcag
CGGGATCCaaagcatatgtagaagaaaagaaag
ACGCCTCGAGttaattagtgccctcttcg
CGGGATCCgatgttagtagattaaatcagagaaatatt
ACGCCTCGAGctataataaagtttgcttaatagctttataag
CGGGATCCatgtgtaaattatatgaaaagcttacaaataaatcgc
CCGCTCGAGttatctagagtccatatcttgcaattt

1084
1085
1023

DbpA_PEPC10 R
C6_PEPC10 F
C6 Bb R

AGGTTTTTTTGGACTTTCTGCCACAACAGGgttatttttgcatttttcatcagtaaaagt
CCTGTTGTGGCAGAAAGTCCAAAAAAACCTatgaagaaggatgatcagattgc
ACGCGTCGACttacttcacagcaaactttccatc

a

a

Uppercase letters indicate non-template sequence used for addition of terminal restriction sites, epitope tags or synthetic
assembly.
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Protein expression was induced by growth of BL21 cells containing the
expression construct for each B. burgdorferi antigen in 50-100 ml Magic
Media E. coli expression medium according to manufacturer’s protocol
(Invitrogen, Carlsbad, CA) for 24 hours at 37°C with aeration. Recombinant
protein purification was performed according to the procedures outlined in the
Bulk GST Purification Module (GE Health Sciences, Piscataway, NJ). Purified
proteins were dialyzed in Tris buffered saline (50 mM Tris-HCl, 150 mM NaCl,
pH 7.5) overnight at 4°C using D-tube dialyzers (EMD Millipore Chemicals,
Philadelphia, PA) and two buffer exchanges to remove excess glutathione.
Dialyzed proteins were subjected to protease cleavage of the GST tag
overnight at 4 °C according to procedures outlined in the PreScission
Protease kit (GE Healthcare, Piscataway, NJ). Cleaved proteins were purified
from GST and excess protease using two rounds of Bulk GST purification (GE
Health Sciences, Piscataway, NJ) and collection of the eluent. Purified
proteins lacking a GST tag were concentrated using Amicon Ultra-2
Centrifugal Filter Devices (EMD Millipore Chemicals, Philadelphia, PA) to a
volume of approximately 80 µl and stored at 4°C. Total protein was quantified
by absorbance spectrophotometry at a wavelength of 280 nm. Recombinant
protein purity and seroreactivity was determined by coomassie gel and
immunoblot using infected mouse serum. Briefly, 100 nanograms of each
recombinant protein were separated by 12.5% polyacrylamide gel
electrophoresis. For coomassie staining, gels were incubated in Imperial
Protein Stain (Thermo Scientific, Rockford, IL) for 1 hour and destained in
deionized water for 1 hour prior to imaging. For immunoblot analysis proteins
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were transferred to a nitrocellulose membrane and the membrane was
blocked in 5% skim milk and incubated for 1 hour with mouse sera collected 3
weeks post inoculation with wild type B. burgdorferi as previously described
[155], diluted 1:200 in Tris buffered saline/0.05% tween pH 7.6 (TBST),
washed twice with TBST, incubated with HRP-conjugated goat anti-mouse
IgG/IgM (Chemicon International, Billerica, MA) for 1 hour, washed twice with
TBST and the signal was detected using the SuperSignal West Pico
Chemiluminescent Substrate Kit (Thermo Scientific, Rockford, IL).
Cloning and Expression of Recombinant
DOC Antigen Lacking GST Fusion Tag
In frame glutathione-S-transferase (GST) fusion protein for the DOC
hybrid protein was generated using two distinct PCR amplification steps.
First, the corresponding coding regions for DbpA and the C6 peptide of VlsE
were amplified separately from B. burgdorferi genomic DNA with non-template
addition of the PEPC10 sequence to each amplicon using primer pairs 1145
and 1084 (DbpA-PEPC10) and 1085 and 1023 (C6-PEPC10), respectively,
engineered with BamHI/SalI restriction sites (Table 2). Both PCR products
were diluted 100-fold, combined and synthetically assembled into the DOC
construct by overlapping PCR using primer pairs 1145 and 1023. Final
constructs were sequenced verified and recombinant protein generated and
purified as described above for the other B. burgdorferi antigens.
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iPCR Reagents, Assay and Signal Amplification
iPCR reagents were prepared and assay conducted as previously
described [155] with minor modifications. Briefly, iPCR assays were
assembled in a two-sided (sandwich) manner as detailed in Figure 10A with
the capability to simultaneously capture and report both IgM and IgG host
generated antibodies (Figure 10B). Recombinant antigens lacking fusion tags
were used to coat magnetic beads for host antibody capture using 10-20 µg of
antigen per mg of beads. Beads were resuspended in 500 µl TBST for
secondary antibody incubation. Signal amplification by real-time quantitative
PCR was accomplished as previously described [155] with the quantification
cycle (Cq) for each reaction determined using manual baseline determination
(Cycle 10-20) and a manual threshold setting of 1.0.
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Figure 10. Schematic representation of multiplex iPCR assay for detection of
Lyme disease host antibodies using recombinant antigens. A recombinant
protein antigen coupled to magnetic beads was used to capture B.
burgdorferi-specific host-generated antibodies (A). A biotinylated DNA
oligonucleotide reporter molecule coupled to a streptavidin-conjugated
reporter antibody was amplified by qPCR for detection and quantification. (B)
The same antigen coupled beads were used to simultaneously capture both
IgM and IgG host generated antibodies which were detected in a multiplex
fashion using isotype-specific secondary antibodies coupled to unique
reporter oligonucleotides (T1 and T2) similarly amplified by qPCR for
quantification.
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Positive Threshold Value and Statistical Analysis
Positive threshold values were established for each individual antigen
using an antigen specific multiplier of the standard deviation (SD) above the
mean value for a group of sixteen healthy individuals. The antigen specific
multiplier was determined using CDC Research Panel I samples as the
training set. The antigen specific multiplier was set at a minimal value where
the samples from all culture positive individuals resulted in a Lyme disease
iPCR positive ΔCq above background. The coefficient of variation (CV) was
calculated as the ratio of the SD to the mean. Sensitivity was calculated as
the ratio of the number of true positives (correctly identified) to combined true
positives and false negatives (incorrectly rejected). Specificity was calculated
as the ratio of the number of true negatives (correctly rejected) to combined
true negatives and false positives (incorrectly identified). Comparisons were
made using the Fisher exact test. P values were 2-tailed and a value of <0.05
was considered significant. All analyses were conducted using Prism
GraphPad (GraphPad Software, La Jolla, CA).

Results
IPCR Demonstrates Strong within Assay Precision and Reproducible
Background across a Sample Population of Healthy Individuals
We previously demonstrated proof of principle for iPCR detection of
human host generated B. burgdorferi antibodies using VlsE C6 peptide coated
magnetic beads and a panel of serum samples (n=36) from Lyme disease
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positive and Lyme disease negative patients and healthy controls [155]. This
feasibility study was accomplished using a small number of healthy samples
(n=5) to establish test efficiency and background threshold levels. In an effort
to establish a better understanding of the Lyme disease iPCR assay
performance, including repeatability and the variability of the background of
the assay across a healthy population, the number of replicates and overall
sample size of healthy individuals was expanded. Prospective blood samples
were collected from consenting individuals without a history of Lyme disease
under the approval of the UCF Institutional Review Board. To assess assay
repeatability, the serum from a single healthy individual was tested eighteen
times using the same reagent preparation lots including DbpA antigen coated
beads and oligo-labeled secondary antibodies. The results of this analysis
demonstrated low within assay variability for both the IgM- and IgG-specific
detection reagents as indicated by standard deviation values for each data set
of 0.39 and 0.73, respectively and a coefficient of variation values for each
data set of 1.34% and 2.30%, respectively (Figure 11).
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Figure 11. Immuno-PCR magnetic bead protocol demonstrates strong within
assay precision. (A) Serum collected from a single healthy individual was
assayed 18 times by IgM/IgG multiplex iPCR using recombinant DbpA antigen
coupled to magnetic beads. (B) The mean, standard deviation (SD), range
and coefficient of variation (CV) (calculated as the ratio of SD to Mean) were
calculated for both IgM and IgG. Each dot represents a single replicate and
the horizontal line represents the mean Cq value for all replicates for each
isotype. The y-axis represents the quantification cycle (Cq) determined by
real time quantitative PCR.

To determine the background variability of the Lyme disease iPCR
assay across a healthy human population, the sera from 36 healthy
individuals were tested in duplicate using magnetic beads coated with the
DbpA antigen and the oligo-labeled IgM and IgG secondary antibodies used
for the repeatability analysis. Similar to the within sample repeatability
analysis, the results of the between sample variability analysis demonstrated
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a standard deviation across the population of 0.79 for the background
detection of IgM antibodies and 0.84 for the background detection of IgG
antibodies and coefficients of variation of 2.66% and 2.63%, respectively
(Figure 12).
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Figure 12. Lyme disease immuno-PCR demonstrates reproducible
background across a healthy human population for both IgM and IgG isotypes
using the DbpA antigen. Sera from 36 healthy individuals were assayed in
duplicate by multiplex iPCR using both (A) IgM and (B) IgG secondary
antibodies and recombinant DbpA antigen coupled magnetic beads. Each dot
represents a single replicate per individual with a horizontal line representing
the mean value for duplicate serum samples from each individual. (C) The
mean, standard deviation, range and coefficient of variation (calculated as the
ratio of standard deviation to the mean) is listed for each isotype. The y-axis
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represents the quantification cycle (Cq) determined by real time quantitative
PCR.

The Mean Background and Standard Deviation Values Across a Population of
Healthy Individuals are Unique for Each Lyme Disease iPCR Assay
Antigen/Isotype Combination
The analysis of the Lyme disease iPCR assay repeatability and
population variability using DbpA coupled magnetic beads demonstrated that
the mean background value for the detection of IgM versus IgG antibodies
differed by as much as ~2.5 Cq (Figure 11 and 12). Based on this
observation, we predicted that depending on the different antigen used each
Lyme disease iPCR assay would each result in a distinct mean background
Cq value. If true, this finding would impact the determination of the
background threshold setting for the assay making it necessary to assign a
distinct background threshold for each antigen/isotype combination. To test
this hypothesis, a panel of 8 recombinant B. burgdorferi antigens either known
or suspected to be seroreactive in humans [87-90, 92, 93, 96, 97, 102] was
generated and purified as in-frame N-terminal fusions to GST. To eliminate
any possibility of antibody cross reactivity to the GST tag, this sequence was
proteolytically removed. The purity and antigenicity of each recombinant
antigen was demonstrated by SDS-PAGE followed by coomassie brilliant blue
staining and immunoblot analysis using pooled sera collected from B.
burgdorferi infected mice (Figure 13).
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Figure 13. Purified recombinant protein panel exhibits antigenicity in infected
mouse serum. Recombinant proteins expressed in E. coli were protease
treated to remove the GST fusion tag followed by subsequent purification to
remove residual GST and protease. Purity and seroreactivity was determined
by (A) coomassie gel and (B) immunoblot using infected mouse serum.

Each antigen was coupled to magnetic beads and examined by iPCR
for both IgM and IgG background reactivity across sixteen serum samples
collected from healthy individuals. As predicted, all antigen/isotype
combinations demonstrated unique background values that ranged from a
mean Cq of 26.09 to 32.46 for IgM and 25.30 to 36.62 for IgG and a standard
deviation of 0.40 to 1.53 for IgM and 0.37 to 1.47 or IgG (Figure 14).
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Figure 14. Immuno-PCR demonstrates low intra-antigen background
variability for an antigen panel across a healthy human population. Sera from
16 healthy individuals were assayed by multiplex iPCR for both (A) IgM and
(B) IgG host generated antibodies against recombinant DbpA, BmpA, OspC,
BBK19, OspA, RevA, Crasp2 and BBK50 antigen coupled magnetic beads.
Each dot represents a single individual replicate and the horizontal line
represents the mean Cq value for all individuals for each antigen/isotype
combination. Each antigen mean and standard deviation (SD) are listed. The
y-axis represents the quantification cycle (Cq) determined by real-time PCR.
The population mean, standard deviation (SD), range and coefficient of
variation (CV) is shown for each antigen/isotype combination.
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Multiplex iPCR Detection of IgM and/or IgG Host Response Antibodies
Against B. burgdorferi Using a Panel of Antigens Provides Equivalent
Sensitivity and Specificity to 2-tier Testing
Most existing protocols for Lyme disease diagnostics require the use of
multiple antigens to diagnose the disease. In an effort to further explore the
application of iPCR as a Lyme disease diagnostic, we sought to determine a
similar methodology that utilizes a combination of results for different antigens
to facilitate diagnosis. The panel of eight B. burgdorferi antigens was tested
against the CDC Research Panel I collection of sera using multiplex iPCR for
simultaneous detection of IgM and IgG host generated antibodies. The same
human serum panel had previously been tested according to CDC guidelines
by commercial ELISA followed by IgM and IgG immunoblot and classified for
2-tier testing status. Samples were classified as Lyme disease positive by
iPCR if they resulted in positive values above the predetermined antigenspecific threshold for IgM or IgG for one or more of the eight antigens tested.
Using this criteria iPCR testing provided similar results to 2-tier testing for the
Lyme disease patient (Table 3) and non-Lyme disease patient (Table 4)
samples with one exception. A single early Lyme disease patient sample,
which was deemed 2-tier negative, tested positive by iPCR (Table 3 sample
A4). It should also be noted that no single antigen provided iPCR-positive
results for all Lyme disease patient samples comprising different stages and
types of disease.
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Table 3. iPCR using eight antigens demonstrates equivalent results to 2-tier testing for CDC Research Panel I

a

Values shown represent the ΔCq above the positive call threshold Cq value determined using an antigen specific multiplier of
the SD above the mean value for a set of healthy individuals for each antigen/isotype combination.
b

Blank boxes represent iPCR values below the positive call threshold.

c

2-tier results established by standard ELISA and IgG/IgM immunoblot
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Table 4. iPCR data for CDC Research Panel I for eight antigens and the DOC hybrid antigen in duplicate IgM/IgG

a

Values shown represent the ΔCq above (gray shading) or below (parenthesis) the positive call threshold Cq value determined using an antigen specific
multiplier of the SD above the mean value for a set of healthy individuals for each antigen/isotype combination.
b

2-tier results established by standard ELISA and IgG/IgM immunoblot
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Simplified Single Hybrid Antigen iPCR Detection of Host Generated IgG
Antibodies Alone Confirms 2-tier Results for a Panel of Human
Serum with Semi-quantitative Determination of Disease Stage
iPCR testing with the panel of eight B. burgdorferi antigens showed
strong potential as a Lyme disease diagnostic by reproducing the 2-tier test
results for CDC Research Panel I samples. Although successful, the use of
multiple antigens tested against IgM and IgG increases test complexity by
requiring testing of a single sample with multiple antigens. In an effort to
further simplify the Lyme disease iPCR approach, we theorized that a single
hybrid antigen composed of the immunogenic epitopes of multiple B.
burgdorferi antigens would provide similar results to testing with a panel of
whole individual antigens. To examine the applicability of a single hybrid
antigen for iPCR detection of host generated antibodies against B. burgdorferi
infection, we synthetically constructed a novel hybrid antigen composed of full
length DbpA, the PEPC10 peptide (OspC) [156] and the C6 peptide (VlsE)
[157] referred to as the ‘DOC’ antigen (Figure 15A). Similar to the previous
eight recombinant antigens, we determined the protein purity and
seroreactivity toward B. burgdorferi infected mouse sera of the hybrid protein
(Figure 13). The range of the background reactivity of the DOC antigen in the
iPCR assay was determined using the serum from a group of sixteen healthy
individuals (Figure 15B). The results of the between sample variability
analysis demonstrated a standard deviation across the population of 0.57 for
the background detection of IgM antibodies and 0.51 for the background
detection of IgG antibodies and coefficients of variation of 2.31% and 1.94%,
respectively. Using iPCR, we then tested the hybrid antigen in duplicate
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against the CDC Research Panel I for IgM and IgG reactivity utilizing the
results to establish a positive call threshold.

Figure 15. Development of a hybrid antigen for simple detection of Lyme
disease. The DOC antigen (A) was assembled using full length DbpA protein
fused to the PEPC10 (OspC) and the C6 (VlsE) peptides and (B) was tested
by iPCR using DOC coated magnetic beads against sixteen healthy
individuals for IgM and IgG for the range of the background reactivity. Each
dot represents a single individual replicate and the horizontal line represents
the mean Cq value for all individuals for IgM and IgG. The mean and
standard deviation (SD) is listed. The y-axis represents the quantification
cycle (Cq) determined by real-time quantitative PCR.

The DOC antigen IgG results confirmed all 2-tier positive results
(Figure 16B). Interestingly, the iPCR assay using the DOC antigen tested
negative for detection of host generated IgM antibodies for all human samples
analysed (Figure 16A).
76

Figure 16. The iPCR assay using the DOC hybrid antigen provides robust
detection of Lyme disease. A serum panel composed of 32 samples and
consisting of Lyme infected individuals both early (acute and convalescent)
and late (neurologic and arthritis) stage as well as look-alike diseases and
healthy individuals from endemic and non-endemic areas was tested in
duplicate using DOC iPCR for both (A) IgM and (B) IgG reactivity. Each dot
represents a single individual replicate and the black horizontal lines
represent the mean Cq value for all individuals within each category. Filled
circles represent samples that were 2-tier positive with open circles signifying
2-tier negative status. A positive threshold value was established using a
multiplier of the standard deviation (SD) above the mean value with the ΔCq
threshold (gray horizontal line) representing a value of zero.
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Although early and specific detection is the primary goal for any Lyme
disease diagnostic, determination of the stage of disease progression would
provide additional information to aide in the treatment of the disease. It is
logical to assume that the amount of host-generated B. burgdorferi antibody
will increase with further disease progression. Due to the quantitative nature
of iPCR testing, we hypothesized that the amount of anti-DOC host generated
IgG antibody would correlate with disease stage. The mean iPCR value was
-1.61 ± 0.36 for acute early Lyme disease patients, 0.67 ± 0.38 for
convalescent early Lyme disease patients and 2.39 ± 0.64 for late Lyme
disease patients for a total of n=4 samples per group. These data suggested
a correlation of increasing anti-DOC antibody with disease progression.
DOC Hybrid Antigen IgG iPCR Demonstrates Improved Sensitivity
and Higher Specificity Compared to 2-tier Testing for a
Blinded Panel of Human Serum Samples
Initial success of DOC IgG iPCR with replicating 2-tier results for a
panel of 32 human serum samples provided strong evidence for the
application of our approach as a simplified Lyme disease diagnostic. We next
sought to perform a larger scale blinded validation analysis of our assay. The
CDC Research Panel II composed of 92 samples including sera collected
from early, cardiac, arthritic and neurological Lyme disease patients as well as
patients with Lyme look-alike diseases and healthy donors was tested by
iPCR for host generated IgG antibodies to the DOC hybrid antigen and
compared to 2-tier test results (Table 5).
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Table 5. iPCR data for CDC Blinded Research Panel II for DOC hybrid antigen IgG
Sample

Sample Group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Early Lyme-EM
Neurologic Lyme
Neurologic Lyme
Neurologic Lyme
Neurologic Lyme
Lyme arthritis
Lyme arthritis

DOC
a
IgG
2.24
2.20
2.07
2.05
1.59
1.45
1.08
0.80
0.52
0.08
(0.08)
(0.27)
(0.58)
(0.91)
(1.00)
(1.01)
(1.22)
(1.48)
(1.50)
1.14
2.64
2.01
0.00
(0.26)
3.44
2.96

iPCR
interpretation
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Pos
Pos
Pos
Neg
Pos
Pos

2-Tier
b
Interpretation
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Pos
Pos
Neg
Pos
Pos

EIA
Interpretation
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Pos
Equ
Pos
Neg
Pos
Pos
Neg
Neg
Neg
Equ
Neg
Pos
Pos
Pos
Pos
Neg
Pos
Pos
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IgM WB
Bands
41, 39, 23
23
41, 39, 23
41
41, 23
41, 39, 23
41, 39, 23
41, 23
23
23
23
23
39, 23
23
23
41
41, 23
41, 39, 23
41, 39, 23
41, 23
23
41

IgG WB Bands
58, 41, 39, 23, 18
66, 45, 41, 39, 23, 18
41, 23
58, 45, 41, 39, 23, 18
41, 23
66, 45, 41, 39, 23, 18
41, 23
41
66, 41, 23
66, 41, 23
66
41, 23
67
23
23
41
41, 23, 18
45, 41, 23
41, 39, 23
41, 23
41, 23
93, 66, 58, 45, 41, 39, 30, 28, 23, 18
93, 66, 58, 41, 39, 30, 28, 23, 18

Sample

Sample Group

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Lyme arthritis
Lyme arthritis
Lyme arthritis
Lyme arthritis
Cardiac Lyme
Cardiac Lyme
Fibromyalgia
Fibromyalgia
Fibromyalgia
Fibromyalgia
Fibromyalgia
Fibromyalgia
Rheumatoid arthritis
Rheumatoid arthritis
Rheumatoid arthritis
Rheumatoid arthritis
Rheumatoid arthritis
Rheumatoid arthritis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Mononucleosis
Mononucleosis
Mononucleosis
Mononucleosis

DOC
a
IgG
2.67
2.62
2.09
1.84
2.83
1.37
(0.28)
(0.81)
(1.70)
(1.89)
(1.93)
(2.30)
(0.90)
(1.17)
(1.56)
(1.73)
(1.77)
(2.05)
(0.55)
(0.78)
(1.09)
(1.11)
(1.75)
(2.05)
(0.09)
(0.28)
(0.58)
(0.77)

iPCR
interpretation
Pos
Pos
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

2-Tier
b
Interpretation
Pos
Pos
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

EIA
Interpretation
Pos
Pos
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Pos
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Neg
Neg
Pos
Pos
Equ
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IgM WB
Bands
41, 23
23
41, 39, 23
41, 39, 23
39
41, 23
39, 23
39
-

IgG WB Bands
93, 66, 58, 45, 41, 39, 30, 28, 23, 18
66, 58, 45, 41, 39, 28, 23, 18
58, 41, 39, 23, 18
93, 66, 58, 41, 39, 30, 23, 18
66, 45, 41, 23, 18
66, 45, 41, 23, 18
23
58, 41
41
41
41
41
41
41, 23
66
39
41, 39
41

Sample

Sample Group

55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82

Mononucleosis
Mononucleosis
Syphilis
Syphilis
Syphilis
Syphilis
Syphilis
Syphilis
Severe periodontitis
Severe periodontitis
Severe periodontitis
Severe periodontitis
Severe periodontitis
Severe periodontitis
Healthy endemic
Healthy endemic
Healthy endemic
Healthy endemic
Healthy endemic
Healthy endemic
Healthy endemic
Healthy endemic
Healthy endemic
Healthy endemic
Healthy endemic
Healthy endemic
Healthy non-endemic
Healthy non-endemic

DOC
a
IgG
(0.78)
(1.25)
(0.56)
(0.75)
(0.96)
(1.01)
(1.38)
(1.47)
(0.22)
(0.29)
(0.56)
(0.90)
(1.03)
(3.04)
0.23
(0.04)
(0.53)
(0.87)
(0.87)
(1.11)
(1.16)
(1.37)
(1.42)
(1.49)
(1.95)
(2.47)
(0.53)
(0.60)

iPCR
interpretation
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

2-Tier
b
Interpretation
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

EIA
Interpretation
Neg
Neg
Pos
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Pos
Neg
Equ
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
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IgM WB
Bands
41, 23
39, 23
41
23
23
23
23
41, 23

IgG WB Bands
66, 58, 41
41
41
41
45, 41
66
23
66
41, 23
41
45, 41
66, 41
58, 41, 39, 18
41
41

Sample

Sample Group

83
84
85
86
87
88
89
90
91
92

Healthy non-endemic
Healthy non-endemic
Healthy non-endemic
Healthy non-endemic
Healthy non-endemic
Healthy non-endemic
Healthy non-endemic
Healthy non-endemic
Healthy non-endemic
Healthy non-endemic

DOC
a
IgG
(0.78)
(0.80)
(0.86)
(0.90)
(1.09)
(1.15)
(1.17)
(1.77)
(2.06)
(2.09)

iPCR
interpretation
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

2-Tier
b
Interpretation
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

EIA
Interpretation
Equ
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Neg
Neg

a

IgM WB
Bands
23
23
-

IgG WB Bands
58, 45
66, 58, 45, 41
41
41
-

Values shown represent the ΔCq above (gray shading) or below (parenthesis) the positive call threshold Cq value determined using an antigen specific
multiplier of the SD above the mean value for a set of healthy individuals for each antigen/isotype combination.
b

2-tier results established by standard ELISA and IgG/IgM immunoblot
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Overall, iPCR provided increased sensitivity and specificity compared
to 2-tier testing results (Figure 17).

Figure 17. DOC fusion antigen IgG iPCR demonstrated improved sensitivity
and specificity compared to 2-tier testing. CDC Research Panel II was tested
in a blinded fashion using DOC iPCR for IgG reactivity. Each dot represents a
single individual replicate and the black horizontal lines represent the mean
Cq value for all individuals within each category. Filled circles represent
samples that were 2-tier positive with open circles signifying 2-tier negative
status. A positive threshold value was established using a multiplier of the
standard deviation (SD) above the mean value with the ΔCq threshold (gray
horizontal line) representing a value of zero. Sensitivity and specificity for
iPCR, each tier and combined 2-tier are listed.
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iPCR replicated all 2-tier positive results. Moreover, iPCR provided
detection of an additional three early Lyme disease samples deemed 2-tier
negative, leading to an overall sensitivity for iPCR of 0.69 with a 95%
confidence interval (95% CI) of 0.50-0.84 compared to 2-tier at 0.59 (95% CI:
0.41-0.76). The difference in sensitivity was primarily for early stage detection
with sensitivity for iPCR at 0.55 (95% CI: 0.32-0.77) and 2-tier at 0.40 (95%
CI: 0.19-0.64) for this category of samples specifically. iPCR and 2-tier
showed equivalent sensitivity for late stage Lyme samples at 0.92 (95% CI:
0.62-1.0). iPCR detected only a single false positive for a healthy endemic
sample providing a specificity of 0.98 (95% CI: 0.91-1.0) as compared to 2-tier
testing that detected two false positives for look-alike diseases providing a
specificity of 0.97 (95% CI:0.88-1.0). For comparison, the sensitivity and
specificity for the ELISA first tier portion of the 2-tier test were calculated to be
0.75 (95% CI: 0.57-0.89) and 0.77 (95% CI: 0.64-0.87), respectively. These
data suggested that while the DOC IgG iPCR assay may be less sensitive
than the ELISA, our assay has improved specificity over the first tier test.
Discussion
There is an urgent need for development of new tools for improved
diagnosis of Lyme disease. This study describes a sensitive, specific and
quantitative Lyme disease diagnostic using iPCR detection of host IgG
antibody binding to a single recombinant hybrid antigen that demonstrates
improved results compared to the 2-tier testing protocol.
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The iPCR Approach is a Repeatable Method that Shows Limited
Background Variability Across a Healthy Population
Repeatability is a key parameter of any newly developed diagnostic
test that provides confidence the test will identify individuals as disease
positive or negative in a reproducible manner across the inherent variability of
a human population. iPCR has been shown to be a reproducible approach for
the detection of other targets [158, 159], although this method generates a
background signal in the absence of the analyte being detected [160]. The
background signal has been attributed to non-specific binding of the
oligonucleotide labelled secondary antibody, similar to results observed for
other immuno-diagnostics [125]. Although a number of approaches have
been proposed to minimize the level of background amplification [121, 161,
162], no approach to date has proven successful at completely eliminating the
background signal. For detection of Lyme disease, we propose that the
background signal provides an intrinsic advantage over standard PCR based
detection due to the buffer zone created between a negative sample and low
level contamination that commonly creates problems for PCR based clinical
diagnostic tests. A positive iPCR result is required to generate an amplified
signal above the background buffer zone. In addition, critical to the success
of this approach is a constant background that remains consistent between
sample replicates and standardized across a healthy human population.
In an effort to determine the consistency of the background
amplification for the technique we tested the serum from a single healthy
individual over eighteen replicates using iPCR and found the standard
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deviation of the mean Cq values to be 0.39 and 0.73 for IgM and IgG,
respectively with corresponding coefficients of variation of 1.34% and 2.30%.
The accepted value for PCR sampling error is ~1 Cq [163] and the coefficient
of variation for an ELISA based test is considered good at less than 15%
[164]. These data indicate that our iPCR protocol can provide highly
consistent and repeatable results across multiple replicates of a single
sample. We proceeded to test serum collected from 36 healthy individuals in
duplicate for IgM and IgG reactivity using the same antigen to determine
variability of the background across a healthy population. Not unexpectedly,
compared to the within sample repeatability analysis, we observed a slightly
higher standard deviation of the mean Cq values of 0.79 and 0.84 for IgM and
IgG, respectively and slightly increased corresponding coefficients of variation
of 2.66% and 2.63%. These data indicate that the assay maintains strong
repeatability even when compounded with normal human population serum
variability. Taken together, these results indicate that the background
variability for iPCR detection of host generated antibodies within and across a
healthy human population is well within acceptable levels for the technique.
Multiple Antigens are Required for Detection of Lyme
Disease Across Multiple Stages/types of Disease
Previous studies using recombinant antigens have indicated that no
single antigen tested to date has the capability to diagnose Lyme disease
across the multiple stages and/or types of disease manifestation [111]. A
panel of eight antigens was generated for use in the iPCR assay. These
proteins were selected based on previous studies that identified B. burgdorferi
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immuno-reactive antigens [102, 165-170]. We first examined the level of
variability of the background amplification of each antigen across serum
samples collected from healthy individuals for both IgM and IgG isotypes.
Each antigen resulted in a unique background amplification mean and
standard deviation for each antigen/isotype combination. This indicated that
each antigen/isotype combination performed uniquely using the current iPCR
protocol. These data provided the necessary parameters including the mean
background Cq value and the standard deviation of that mean for
determination of an individual call threshold for each antigen/isotype
combination. The call thresholds were established as the mean background
Cq value minus a multiple of the standard deviation. The multiplier of
standard deviation was unique for each antigen/isotype combination and
established based on the maximum multiplier that resulted in no false positive
calls for the CDC Research Panel I, which served as the training set for
optimization of our assay. The ΔCq was calculated as the established
threshold call Cq minus the Cq value of the sample. A sample with a ΔCq
value ≥0 was deemed positive by iPCR. Using the panel of eight antigens,
this approach duplicated 2-tier testing results with a single early Lyme disease
patient sample (culture positive) testing positive by iPCR that was negative by
2-tier, suggesting an increased level of sensitivity. Samples from individuals
in later stages of the disease (neurologic and arthritis) tended to test positive
for multiple antigens.
In addition to detecting the presence of host antibodies and
subsequent disease diagnosis, it is important to determine the clinical stage
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(i.e., neurological, arthritic, cardiac) of a patient to better understand disease
progression. Results from human serum panel iPCR testing classified both
late Lyme arthritis samples as strongly positive for IgG using RevA and
Crasp2 proteins with all other categories of samples testing negative for the
same two proteins. This result suggests that these two proteins may
specifically illicit an immune response in arthritic Lyme disease as opposed to
other types of Lyme disease. Other studies have shown RevA to be
expressed early in human infection [170] and it has been evaluated as a
potential vaccine target [171] but no studies have yet linked it to a particular
disease type such as arthritis. Crasp2 has been shown to illicit a long-term
immune response in a mouse model [172] and explored for use in serological
assays [173] but similar to RevA, has yet to be correlated with a disease type.
RevA and CRASP-2 have been demonstrated to bind fibronectin and factor H,
respectively. Interestingly, a theory has been proposed in which persistence
of B. burgdorferi infection could be due to the organism coating itself in host
macromolecules (i.e., fibronectin) resulting in a decreased immunogenicity
combined with protection from complement mediated lysis thus leading to
secondary and tertiary stages of the disease including late stage arthritis
[174]. This hypothesis would support the preliminary result observed for
these two antigens by iPCR testing. However, additional samples would be
required to further support these observations.
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DOC Single Hybrid Antigen iPCR Detection of Host Generated IgG
Antibodies Provides a Simple Quantitative Lyme Diagnostic
Limited studies have shown promising results using antigens
composed of multiple antigenic portions of various seroreactive proteins to
detect B. burgdorferi antibodies in human patient sera [169, 175, 176].
Demonstration of iPCR equivalency to 2-tier testing using a panel of antigens
led us to surmise that a more simplified version of the protocol using a single
hybrid antigen was likely to be successful. Three antigens known to be
seroreactive at different stages of the disease (DbpA, OspC and VlsE) were
synthetically joined by combining the sero-reactive peptide portions of OspC
[177] and VlsE [178] with the full length DbpA protein into a single
recombinant hybrid antigen we termed ‘DOC’. The mean background was
established for sixteen healthy individuals using DOC and showed little
variation (standard deviation of 0.57 and 0.51 for anti-B. burgdorferi IgM and
IgG antibodies) similar to the full length antigens tested. The DOC antigen
was then used to test a CDC Research Panel I for anti-B. burgdorferi IgM and
IgG antibodies for establishing a positive call threshold. DOC iPCR IgG
results demonstrated equivalent results to 2-tier testing with all 2-tier positives
showing positive by iPCR. The quantitation of the ΔCq for Lyme disease
patients showed a trend with increasing average values from early Lyme
acute (-1.61) to early Lyme convalescent (0.67) to late stage Lyme (2.39)
suggesting a correlation of the amount of detectable B. burgdorferi antibody
with disease stage. Surprisingly, DOC iPCR IgM was negative for all samples
tested including Lyme disease patient samples. These results indicate that
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only testing of the IgG fraction using the DOC hybrid antigen is necessary for
Lyme disease diagnosis by iPCR and there exists a potential for
determination of the stage of disease based on the ΔCq value.
iPCR testing of the anti-B. burgdorferi IgG antibody fraction using the
DOC hybrid antigen was successful at duplicating the 2-tier testing results for
a small panel of samples. We then proceeded to test a larger blinded panel of
92 samples composed of serum from Lyme disease patients (early, cardiac,
arthritis and neurologic), look-alike diseases (fibromyalgia, mononucleosis,
multiple sclerosis, rheumatoid arthritis, severe periodontitis and syphilis) and
healthy (endemic and non-endemic) individuals (CDC Research Panel II).
iPCR demonstrated increased sensitivity (0.69) and specificity (0.98)
compared to 2-tier testing (0.59 and 0.97), respectively. iPCR provided the
highest level of specificity when compared to each individual tier and was only
surpassed in sensitivity by tier-1 ELISA testing (0.75) which also resulted in
the lowest level of specificity (0.77). A single neurologic Lyme disease patient
tested negative by both iPCR and 2-tier testing. This result is most likely due
to the fact that the serum sample was taken 7 days post EM, which was likely
too early in infection to produce an adequate immune response.
Application of DOC IgG iPCR as a Future Lyme Diagnostic
For clinical testing, larger cohorts are needed to further standardize the
assay and establish the exact cut-off needed to classify the borderline-positive
samples as healthy or Lyme disease positive. Currently, the DOC hybrid
antigen is composed of B. burgdorferi B31 sequences. Amino acid
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sequences can vary between strains and species of Lyme disease Borreliae
by as much as 24% for VlsE C6 [157], 10% for OspC PEPC10C [156] and
44% for DbpA [179]. This may be limiting if an individual is infected with other
strains or species. It is likely that the incorporation of additional
protein/peptide sequences from other species, such as B. afzelii or B. garinii,
or other strains might further increase the sensitivity of the assay, especially
when samples from patients with Lyme disease from Europe and other
diverse locations are analysed.
In summary, DOC IgG iPCR shows extraordinary potential as a novel
diagnostic tool for identifying host generated antibodies against B. burgdorferi.
It will be of interest to determine whether this test is useful for monitoring
antibody titre changes over time in samples from patients after antibiotic
therapy for Lyme disease to determine the stage of disease as well as
exploration of specialty testing using this approach to determine the type of
disease manifestation.
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CHAPTER FOUR:
CONCLUSION

Synthesis and Implications
Lyme disease is the most common tick-borne bacterial disease in
North America. According to the Centers for Disease Control and Prevention,
Lyme disease is the fastest growing tick-born disease in North America, with
greater than 30,000 annual confirmed cases reported in United States and an
estimated 300,000 infections every year [13]. Borrelia burgdorferi is the
causative bacterial agent of Lyme disease in the United States and a
spirochete that stains gram negative. Using microscopy, it is typically
characterized by its corkscrew morphology and periplasmic flagella. B.
burgdorferi cycles between small rodents and hard ticks including Ixodes
scapularis in the Northeastern and Midwestern United States and Ixodes
pacificus in Western states [180]. The organism does not cause disease
symptoms in the tick or the mouse, both of which serve as reservoir hosts.
Lyme disease outbreaks typically correlate with seasonal changes in tick
activity with the height of transmission during late spring. Humans are not a
natural host for B. burgdorferi but are infected when fed upon by an infected
tick, resulting in disease manifestation following transmission of the organism.
Lyme disease is an immunopathologic response to Borrelia burgdorferi and
has three stages of infection. The first stage is an early, localized infection
characterized by erythema migrans (EM) or a ‘bull's eye’ rash that appears 3
to 30 days after a tick bite. This rash symptom is seen in about 75% of the
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infected population. Other signs of early stage infection include fatigue, chills,
fever, and headache. The next stage of infection is an early, disseminated
infection, which results from dissemination of spirochetes to distant tissues
like joints, heart, bladder, central nervous system and secondary skin sites.
The final stage of infection occurs late and is characterized by arthritis,
carditis and meningitis [180]. Antibiotic treatment for a duration of two weeks
has shown to be successful following proper diagnosis. If gone untreated,
Lyme disease is often difficult to treat in the advanced stages [181]. No
accepted vaccine is currently available for Lyme disease so improved
methods for diagnosis and treatment are necessary and continue to be
important areas of research interest.
Accurate diagnosis of Lyme disease poses one of the greatest
challenges to the clinical management of the disease. Misdiagnosis is
common as the clinical manifestations of the disease are not unique and
detection of a B. burgdorferi infection is difficult and prone to misinterpretation
[111, 129]. There is great need for the development of improved methods for
the definitive diagnosis of Lyme disease. iPCR is a powerful and highly
versatile approach for the detection of protein antigens and the host response
antibodies that are produced against those antigens [126, 162]. This
methodology combines the sensitivity of PCR with the specificity and
versatility of ELISA-based protocols [118] and is an excellent technical tool for
detection of low level proteins including antibodies.
The dissertation presented addresses the hypothesis that the
application of iPCR to detection of B. burgdorferi infection will result in an
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improved diagnostic method for detection of Lyme disease. The studies used
to support this theory focused on the development and application of iPCR for
detection of host-generated antibodies to B. burgdorferi and comparison of
the approach to the currently accepted diagnostic methods for Lyme disease
using an experimental mouse model of infection as well as human Lyme
patient serum samples.
iPCR Demonstrates the Capability for Both Direct and
Indirect Detection of Multiple B. burgdorferi Targets
The iPCR methodology is similar to that of a two-sided (sandwich)
immunoassay in which the target protein is acquired between a capture
antibody or antigen and a reporter antibody (Chapter 2, Figure 4). In contrast
to an ELISA, which uses an enzyme/substrate detection system, the detection
system for iPCR is quantitative PCR amplification of a specific DNA molecule
conjugated to the reporter antibody [118, 120, 126, 162]. PCR amplification of
the DNA reporter results in exponential amplification of the output signal
allowing detection of rare biomarkers in complex biological samples [118, 122,
149, 182-184]. Similar to enzyme immunoassays, the specificity and
versatility of iPCR is determined by the specificity of the capture and reporter
antibodies for the target antigen [162]. The flexibility of the iPCR approach
was demonstrated by capture and direct detection of intact B. burgdorferi
(Chapter 2, Figure 9) and indirect detection of host generated antibodies in
serum of B. burgdorferi infected mice (Chapter 2, Figure 6) using a similar
magnetic bead capture methodology. Similarly, it was shown that a variety of
antigens including intact spirochetes (Chapter 2, Figure 6) as well as single
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recombinant antigens (Chapter 2, Figure 7) could be used to capture hostgenerated antibodies in the serum of B. burgdorferi infected mice. The
flexibility of the iPCR approach is advantageous and important for a disease
such as Lyme disease where measurement of a single disease marker is
unlikely to provide a comprehensive diagnostic assay. Although multiple
target detection is compatible with other diagnostic systems [185], it has been
suggested that with careful selection of multiple capture/reporter antibody
combinations along with unique DNA reporter molecules, iPCR assays may
be capable of concurrent detection of several protein biomarkers in the same
sample [186]. This possibility of multiplex analysis of a single sample is
particularly intriguing for the development of a detection method for Lyme
disease biomarkers as it would provide the ability to identify and quantitate the
presence of several B. burgdorferi antibodies and/or antigens at the same
time (Chapter 3, Figure 10B) and ultimately could lead to the ability to
determine the specific Borrelia species that caused the infection and/or to
determine the disease stage of the patient. We have demonstrated that using
iPCR both IgM and IgG host antibodies generated against a B. burgdorferi
infection could be captured and detected simultaneously using magnetic
beads coated with single B. burgdorferi antigen (Chapter 2, Figure 7 and 8). It
is intriguing to extend this same concept to detection of not only additional
host antibody isotypes such as IgA [185] or IgE [187] but also provide the
capability of concurrent direct detection of B. burgdorferi antigens within the
same sample. This same multiplex-based approach would be difficult if not
impossible with other diagnostic methods that typically employ a single
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reporter molecule such as an enzyme that is incapable of differentiating
multiple targets in a single sample. It is important to note that multiplex
detection of multiple antigen types for purposes of increasing specificity,
species identification and/or disease staging would require improvements on
the current iPCR protocol described here. The current protocol does not
differentiate between antigen types conjugated to the magnetic beads but only
the host antibody isotypes that bind a single antigen type. Methods for
determining antibody binding to multiple bead conjugated antigens would
require a more sophisticated approach that would combine the capability to
distinguish both bead type and antibody binding status simultaneously. This
could theoretically be accomplished by combining a digital PCR approach
[188] with established methods for multiplex microsphere analysis [189] in a
single platform. Although technically challenging, this could provide a viable
method for multiplexing both antigens as well as antibody isotypes for a more
complete picture of host immune response.
iPCR Utilizing Intact B. burgdorferi Shows Improved
Sensitivity Using a Mouse Model
In addition to the ability to detect multiple targets, sensitivity is a key
parameter required for diagnosis of Lyme disease particularly in the early
stages of disease when levels of host antibody can be quite low. Because of
its signal amplification power, iPCR demonstrates a 100-10,000 fold increase
in the typical detection limit of the ELISA [120]. The specificity and sensitivity
of iPCR makes it a highly effective method for diagnosis of infectious
diseases. Indeed, iPCR has been used for ultrasensitive detection of viral
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and bacterial pathogens and antibodies [121, 125, 147-149, 190-194]. In
recent years vast improvements have been made to iPCR protocols,
surmounting many of the difficulties, such as high background and lack of
reproducibility, which have impeded the use of iPCR as a microbiological
diagnostic tool in clinical laboratories [127]. It was demonstrated that iPCR
using intact spirochetes to capture host-generated antibodies provided earlier
detection (day 11) than either a commercial ELISA (day 14) or standard
immunoblot (day 21) for a murine infection model (Chapter 2, Figure 6).
These data have strong implications for iPCR detection of Lyme disease in
humans. Typically, detection of host antibody response is less successful in
early stage of Lyme disease due to extremely low levels of circulating
antibodies to the spirochete. A diagnostic method such as iPCR that
demonstrates more sensitive, and hence earlier, detection of B. burgdorferi
antibodies provides the opportunity to begin treatment in a timelier manner
which will ultimately minimize complications due to infection.
iPCR Using Recombinant Antigens Further Improves Sensitivity
and Demonstrates Strong Correlation with a Commercial
ELISA For Human Serum Samples
The initial iPCR assay design for capturing host antibodies against B.
burgdorferi employed magnetic beads coated with intact spirochetes.
Although this method proved successful, it resulted in only a small positive
difference between uninfected and infected mouse serum. These data
suggested that only a minor percentage of the proteins exposed on the
surface of the B. burgdorferi were antigenic and therefore capable of
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capturing host antibodies generated in response to a B. burgdorferi infection.
It therefore seemed reasonable to hypothesize that the use of specific
recombinant in vivo-expressed B. burgdorferi antigens as the bait for the host
response antibodies would likely provide improved sensitivity. The basis for
this hypothesis was that magnetic beads coated in specific in vivo-expressed
antigens would provide optimal presentation of an increased concentration of
a specific target for host antibody capture as opposed to a reduced
concentration of multiple targets that would be presented on the surface of a
whole spirochete. This was found to be the case as demonstrated by
detection of host response antibodies against B. burgdorferi at day 7 post
inoculation in the mouse model of infection using magnetic beads coated in
two distinct recombinant antigens (Chapter 2, Figure 7) as opposed to at day
11 post inoculation using magnetic beads coated with intact spirochetes
(Chapter 2, Figure 6). Although specificity was not analysed in these
experiments, it also seemed likely that the use of single B. burgdorferi-specific
in vivo-expressed antigens would reduce the opportunity for cross-reactivity,
which may occur with a higher frequency when the antibody capture systems
uses antigens that are highly conserved across microorganisms, such as
flagellar proteins [195]. The use of carefully selected B. burgdorferi-specific
antigens provided the opportunity to reduce or potentially eliminate crossreactivity, screen for the antigens that demonstrated the highest sensitivity
and potentially apply a select multi-antigen approach that may detect
antibodies developed against antigens differentially expressed across the
disease spectrum. As stated earlier, host generated antibodies during a B.
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burgdorferi infection can vary significantly by the type and stage of infection,
strain and species of the infecting spirochete as well as the range of immune
responses elicited by different individuals. All in all, our preliminary data using
a mouse infection model demonstrated the feasibility and strong performance
of iPCR-based detection of B. burgdorferi antibodies in infected animals.
The next step in development of the iPCR-based assay for detection of Lyme
disease was to determine applicability of the approach for testing in human
samples.
To determine preliminary feasibility for Lyme disease testing of human
samples with our assay, the next step in development was to determine assay
performance for a small cohort of individual samples. Although promising, the
improved sensitivity the iPCR-based method demonstrated over current
methods with a mouse model may not accurately predict the performance and
varied background encountered when testing human patient samples. For
instance, a population of individuals from different parts of the country would
likely be exposed to a number of different strains and present potentially
different immune responses to the same strain. In addition, different immune
histories (i.e., exposure to other pathogens) could also potentially affect test
specificity, as antigens from microorganisms other that B. burgdorferi have the
possibility of generating antibodies that are cross reactive with B. burgdorferi
antigens. To explore these issues, preliminary testing utilized a panel of
human serum samples from Lyme positive and negative individuals whose
disease status was determined by the Centers for Disease Control using a
commercial ELISA for combined IgM/IgG reactivity to the VlsE C6 antigen.
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iPCR analysis of the human panel for IgM and IgG individual reactivity using
the VlsE C6 peptide antigen demonstrated strong agreement with the
commercial ELISA (Chapter 2, Figure 8) and as mentioned earlier was able to
separately quantitate both IgM and IgG response as opposed to the combined
IgM/IgG measurement of the commercial ELISA. All samples positive by
ELISA resulted in a positive iPCR call for either IgM or IgG. More
importantly, a small subset of samples that tested equivocal or negative by
ELISA was found to be positive by iPCR. This result further supported the
earlier mouse model observation of increased assay sensitivity for iPCR
compared to existing methods. In addition, iPCR demonstrated no false
positive results for non-Lyme disease and healthy individuals suggesting high
overall specificity for the assay. Due to the small sample size, these results
were considered preliminary and required additional testing of human
samples to support these conclusions. Nonetheless, the overall results
provided strong evidence for iPCR applicability to Lyme disease testing in
human samples as a more sensitive method for indirect detection of host
generated antibodies.
iPCR Provides a Potential Method for Direct Detection of B. burgdorferi
Indirect detection of host immune response by ELISA and immunoblot
is the current accepted method for diagnosis of Lyme disease [106]. PCR
detection is not recommended under CDC guidelines and culture of the
organism from patient blood or tissue is not typically undertaken in a clinical
setting [111]. This is primarily due to the fact that B. burgdorferi spirochetes
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are found transiently in blood, in such low numbers (0.1-1.0 cfu/ml) and
require more specialized culture conditions than other organisms [111]. Due
to the fact that iPCR has demonstrated success at detection of low levels of
organism in bodily fluids for other pathogens [121, 122], it was important to
determine the potential for applying the same approach for direct detection of
B. burgdorferi in blood. Results with a mouse model (Chapter 2, Figure 9)
demonstrated that direct capture and detection of B. burgdorferi whole
organism from blood using iPCR did not reach adequate levels of sensitivity
needed based on the predicted low levels of cultivable cells per millilitre of
blood in an active human infection. The iPCR method reproducibly detected
1,000 spirochetes/ml; however, detection of spirochetes in human blood
would require at least 1000-fold greater sensitivity. There exists potential to
use iPCR as opposed to PCR for earlier detection of enriched blood culture
positive samples as it not only directly detects B. burgdorferi proteins but also
provides minimal chance of false positive results due to laboratory
contamination, which is a major challenge for PCR detection methods.
Additional method development for this purpose would be required and would
include testing of alternative antibodies for increased capture sensitivity and
protocol optimization for spirochete capture in blood culture medium.
The preliminary work described in the first section of this dissertation
provides the initial report for the first successful application of iPCR for indirect
detection of Lyme disease. Methodologies and current limitations for
detection of both host response antibodies to a B. burgdorferi infection and
the spirochete itself were demonstrated suggesting potential applications as a
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new and more sensitive Lyme disease diagnostic using primarily indirect
detection of host generated antibodies. With initial success in human
samples, the next stage of development comprised expanded development of
the assay and qualification for testing of human Lyme samples.
iPCR Assay Multi-Antigen Development and
Qualification as a Human Lyme Diagnostic
With promising results for human sample testing with our iPCR assay,
the next step in development was to determine the repeatability and
background signal of the iPCR assay for human samples collected from
healthy individuals. iPCR, similar to other immuno-based detection methods
such as ELISA, results in a normal background signal attributed to nonspecific binding of the detection reagents to the solid support matrix. The
presence of a background signal makes it important to determine the
variability of the background signal for both the technique itself as well as
normal variation within the healthy human population. Intra-assay variation
was tested by examining multiple replicates of the same serum sample for
both IgM and IgG reactivity with a single antigen (Chapter 3, Figure 11), which
resulted in strong repeatability for the assay itself. This result was expected
based on a small number of replicate samples tested during earlier
development work. Of more interest was the variation across a normal
human population to determine if the background was indeed reproducible
across groups of healthy individuals. A normal background is important for
immunoassays like iPCR due to the need to establish the range of values for
healthy individuals to determine the threshold cut-off value for the assay that
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distinguishes a negative from a positive result. Intra-assay human population
variability (Chapter 3, Figure 12) demonstrated a slight increase above the
intra-assay technique variability. This result is not unexpected as different
individuals with varying immune histories would likely not provide the same
background values. Following establishment of iPCR technique repeatability
for human samples, the next step was to focus on improving the host antibody
capture capabilities of the assay.
Because of the limitations of direct detection of B. burgdorferi in patient
samples, the majority of current Lyme disease diagnostics rely on detection of
host response antibodies to B. burgdorferi infection as recommended by the
CDC [114]. The first-tier ELISA is the most common type of test performed to
detect antibodies against B. burgdorferi [111] but this method does pose
some challenges to the clinical diagnosis of Lyme disease. The major
drawback to the approach is a lack of required standardization which leads to
variation within and between commercial kits which can increase the potential
for misdiagnosis [111]. Antibody capture using whole-cell sonicates of B.
burgdorferi as the capture antigen(s) tends to lack specificity due to the
presence of conserved, highly cross-reactive antigens [111]. An additional
challenge to the accurate detection of Lyme disease is that there are multiple
Borrelia species that are able to cause the disease [180]. Genetic variability
has been documented across isolates [65, 111, 196-198], which suggests that
different species and different clinical isolates of the same species may have
distinct antigen expression profiles resulting in discrete serological patterns
that may not be detectable by single antigen ELISA methods [111]. As a
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result, immunodiagnosis of Lyme disease is highly dependent on antigen
selection. For this reason, a panel of multiple antigens was examined using
iPCR to identify those antigens that demonstrate high sensitivity and
specificity in our assay.
A group of antigens previously shown to be sero-reactive in mammals
(mouse or human) were expressed as recombinant proteins in E. coli. iPCR
background signal was then established for each antigen using a sample of
healthy individuals. Each antigen/isotype combination provided a unique
mean amplification cycle and standard deviation (Chapter 3, Figure 14) for the
cohort of healthy samples. For any quantitative assay that generates a
background signal in healthy samples, determining the positive call threshold
first requires establishment of the mean value and standard deviation for
healthy individuals. Typically, three times the standard deviation above the
mean is applied for determining the call threshold in ELISA based assays
[164]. Although the threshold value cut-off for iPCR was determined using
three times the standard deviation of the background amplification of serum
from healthy individuals in the initial stages of development of the assay
(Chapter 2, Figures 6-8) it became apparent that due to the variation in means
and standard deviation values between antigens and antibody isotypes, each
antigen/isotype pair would require a unique empirically determined multiplier.
It was determined that the multiplier would be established by testing a panel
of known Lyme positive and negative samples, supplied by the CDC, for each
antigen/isotype combination and adjustment of the standard deviation
multiplier to a minimal value that would correctly identify the status of all
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positive samples. Hence, the eight recombinant proteins were tested against
a training panel of 32 human samples including Lyme patient samples from
different stages/types of disease, look-alike diseases and healthy endemic
and non-endemic controls (CDC Research Panel I). The disease status for
each sample had been established previously by standard two-tier testing
using a first tier ELISA and second tier immunoblots for IgM and IgG. iPCR
confirmed all two-tier positive samples with an additional early Lyme sample
testing positive by iPCR but negative by two-tier analysis (Chapter 3, Table 3
and Table 4). Similar to the higher sensitivity observed for iPCR detection of
B. burgdorferi antibodies in the previous human panel and mouse model, this
result further supported higher sensitivity detection of host generated
antibodies compared with two-tier testing. All samples negative by two-tier
were similarly confirmed negative by iPCR also demonstrating the strong
specificity of the approach.
The current national guidelines for serological diagnosis of Lyme
disease recommend two-tier testing, in which a positive ELISA is followed by
immunoblot analysis for specific IgM and IgG antibodies [114]. Although the
two-tier protocol has improved diagnosis of Lyme disease [111], analysis of
immunoblot results requires technical expertise and is prone to subjectivity
leading to potential misinterpretation [154]. In addition to increased sensitivity
and specificity, a goal for examining the iPCR approach as a method for
diagnosing Lyme disease was to apply a technique with objective quantitative
results with minimized technical complexity as a potential to replace two-tier
testing. Although successful at demonstrating increased sensitivity, an iPCR
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protocol that requires the use of a panel of individual B. burgdorferi antigens
would impart an undesirable complexity to the assay. This is due to the fact
that each antigen would require testing of a separate fraction of serum for
each individual. Although IgM and IgG could be tested simultaneously due to
the multiplex capability of iPCR, the existing panel of eight antigens would
require testing of eight aliquots for each individual resulting in a more complex
testing and analysis scheme. A more efficient solution would be to combine
appropriate antigens into a single hybrid antigen to further minimize the
complexity of the iPCR method for Lyme disease.
Numerous ELISA and immunoblot Lyme disease diagnostic methods
have been developed using specific B. burgdorferi recombinant antigens
[111]. Strong assay sensitivities have been shown for other Lyme disease
diagnostics when multiple purified antigens are used in combination [144,
169, 199]. Moreover the data presented herein as well as the data from other
groups demonstrate that there is no one single B. burgdorferi antigen that
appears to be diagnostic for Lyme disease (Chapter 3, Table 3 and [111]). As
opposed to utilizing a combination of full length proteins, our strategy involved
expressing a recombinant hybrid protein using a design scheme that coupled
known immunodominant peptides to a highly expressed, small and
established seroreactive protein. The DbpA antigen was selected as the full
length “anchor” antigen, which has been shown to maintain uniformly high
antibody titers in non-human primates throughout the course of disease [107,
200]. The immunodominant peptides for both the VlsE and OspC antigens
have been mapped [201, 202], studied [203, 204] and utilized in other
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diagnostic formats [205, 206]. The synthetic peptide C6, which represents the
invariable region of the VlsE protein is a strong target for IgG antibodies early
in Lyme disease progression [144, 178]. The OspC-derived peptide,
PEPC10, also has demonstrated a strong immune response in Lyme disease
patient sera during early stages of infection [144, 177, 203]. We generated a
recombinant hybrid protein that coupled the amino acid sequences of
PEPC10 and C6 to the C-terminus of the full length DbpA protein (Chapter 3,
Figure 15A). The mean background and standard deviation in a healthy
human population was determined for the hybrid antigen we termed ‘DOC’
(Chapter 3, Figure 15B).
The DOC antigen was then tested in a similar manner as the panel of
eight antigens for both IgM and IgG iPCR reactivity against the panel of 32
human sera from CDC Research Panel I. The DOC IgG results using iPCR
confirmed two-tier testing results for positive samples with no discrepancies
(Chapter 3, Figure 16). Additionally, all look-alike disease and healthy
samples tested similarly tested negative by both iPCR and two-tier testing
(Chapter 3, Figure 16). Surprisingly, all samples tested negative by DOC IgM
iPCR for Lyme disease patient, look-alike disease and healthy samples.
Taken together, these results indicated that only testing of the IgG fraction of
a sample was required using the DOC antigen and iPCR for 100% correlation
with the two-tier results supplied by the CDC. Although surprising, this result
indicated a unique and strong benefit to our approach. Depending upon the
stage of infection and antigen expression pattern, B. burgdorferi may elicit IgM
and/or IgG antibody production [207]. The guidelines for immunoblot
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interpretation for two-tier testing state that IgM or IgG criteria [99, 110] may be
used in the first month of infection. However, immunoblot interpretation is
then limited to IgG criteria only after 4 weeks following disease onset, as IgM
has been shown to persist post-treatment despite resolution of the infection,
making interpretation difficult [98, 207]. This means the time-sensitive use of
IgM may not only limit assay sensitivity in the event that IgG antibodies have
not fully developed at time points just beyond 4 weeks of infection [208] but
also contribute to the complexity, cost and convoluted analysis of the two-tier
method. Our preliminary result with the DOC antigen IgG reactivity indicated
that only a single tier single isotype test was required to confirm two-tier
testing resulting in a significantly simplified protocol for Lyme disease testing
that avoids the controversy associated with IgM interpretation.
Beyond IgM interpretation, immunoblot analysis for Lyme disease is
subjective and provides only qualitative results for host antibody levels. iPCR,
due to the incorporation of quantitative-PCR, provides a means for
quantitatively determining the level of host generated antibodies in a serum
sample similar to the first-tier ELISA. Beyond confirmation of overall two-tier
results, the values established for each positive sample by iPCR for the panel
of 32 samples appeared to correlate with disease stage (Chapter 3, Figure
16). For instance, early stage Lyme samples ranged from 0.45 to 1.24 with
an average ∆Cq of 0.67 (SD=.038). Later stage Lyme samples (neurologic
and arthritis) had a ∆Cq range of 1.45 to 2.86 with an average of 2.39
(SD=.64). This equates to slightly more than 3-fold higher antibody titres on
average in later stage disease samples. These early results suggest the
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possibility of applying iPCR for quantitatively estimating the stage of disease
progression. This could provide valuable information to help address
difficulties in treating Lyme disease at later stages of progression. These
results should be considered preliminary and would be further supported with
additional testing of well-characterized human samples.
Following successful testing of DOC IgG iPCR using a panel of known
human serum samples, we next tested our optimized assay against a larger
blinded panel of 92 human serum samples (CDC Research Panel II). The
panel was similarly composed of samples from confirmed Lyme disease
patients, patients with look-alike diseases and healthy individuals from
endemic and non-endemic areas. Confirmation of positive Lyme patient
status was established by the presence of single or multiple EM, culture reisolation of live B. burgdorferi organism and B. burgdorferi locus specific PCR
from EM skin samples. The results from these analyses demonstrated the
optimized single antigen approach was capable of detecting all two-tier
positive samples with an additional three early Lyme disease patient samples
detected by iPCR that were not detected by the two-tier protocol providing a
sensitivity of 0.69 compared to 0.59 for two-tier testing (Chapter 3, Figure 17).
Only a single false positive was observed for iPCR compared to two false
positive samples for two-tier testing providing a slightly higher specificity (0.98
compared to 0.97). These results confirmed the trend evident in both the
mouse model as well as earlier testing with other human panels, that iPCR is
a more sensitive approach than two-tier testing for diagnosis of Lyme disease
in human serum samples. Additionally, iPCR results for specificity were also
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slightly improved compared to the existing two-tier protocol. Taken together,
these results provide strong support for further exploring the potential to
replace current complex and labour intensive two-tier Lyme disease testing
with the simple, cost effective, objective and quantitative method of single
hybrid antigen IgG iPCR.
Impact on Human Lyme Disease Diagnosis
Certain sectors of society including individuals within the medical
community have referred to Lyme disease as a chronic infection that is
difficult to treat and in some cases can require prolonged antibiotic treatment
for later stage disease. Although the CDC has issued recommended metrics
for diagnosing individuals infected with B. burgdorferi [106], diagnoses are at
the physician’s discretion. Improper analyses of diagnostic test results from
immunoblot analysis alone or the interpretation of IgM immunoblot banding
patterns beyond four weeks of infection have resulted in controversial
determinations of disease status. In response to incorrect test analysis,
suspected Lyme disease patients may undergo expensive, long-term
intravenous antibiotic treatments. This is in direct contradiction to results from
more recent clinical trials [209] that found no significant difference in the
outcome for Lyme disease positive or negative patients for prolonged
antibiotic treatment as compared with placebo. It has also been established
that extended courses of antibiotic therapy administered beyond the
recommended time course can actually negatively impact a patient’s health
status [210]. A more objective and less complex diagnostic test for Lyme
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disease, such as out iPCR assay, may provide a more concise laboratory
result reducing the opportunity for misdiagnosis based on incomplete or
misunderstood clinical laboratory data.
Earlier diagnosis of Lyme disease typically has a strong prognosis for
recovery with the recommended two week regiment of oral antibiotics [211].
However, if gone undetected, progression of Lyme disease can result in
cellular damage and long term physical ailment [212]. This means the earlier
and more accurately a B. burgdorferi infection can be detected and proper
treatment initiated, the better the outcome and the less chance for
unnecessary treatment due to either a false positive results using existing
testing or more radical treatment based on incomplete diagnostic results.
Current controversies surrounding diagnosis and treatment of Lyme disease
highlights the importance for an improved more sensitive and more specific
diagnostic [213]. iPCR was demonstrated to have superior sensitivity to twotier testing with particular improvements for detection of early disease. The
DOC IgG optimized iPCR also demonstrated increased specificity over twotier testing resulting in fewer false positive results for the serum samples in
the CDC Research Panel II. The results for iPCR are quantitative and
unambiguous and eliminate the need for IgM analysis, which remains a
controversial topic in Lyme disease diagnostic research. The potential to
reduce analysis to a simple single tier will also reduce the cost and complexity
of Lyme disease diagnosis, simplify test result analysis and provide a more
timely analysis of samples reducing the time to treatment for individuals that
test positive. Taken together, iPCR detection of Lyme disease has
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demonstrated the capability to provide a more effective means of diagnosing
Lyme disease.
Future Directions
Reagent Optimization
One of the strengths of our iPCR approach is the use of a liquid phase
capture of host-generated antibodies using antigen coupled magnetic beads.
To accomplish the conjugation, a single commercial kit chemistry was used
based on an epoxy surface chemistry (Dynabeads Antibody Coupling Kit,
Invitrogen, Carlsbad, CA). Additional commercial methods are available for
linking ligands (antigens, antibodies, proteins, etc.) to solid supports such as
magnetic beads using a number of different covalent linkages. The chemical
reactions that facilitate ligand attachment are well characterized and proceed
by attachment of biomolecules through common chemical groups.
The diagnostic performance of a coupled antigen can be affected by
the type and number of linkages formed between the bead and the protein.
For example, if the approach for linking the antigen to the bead adversely
affects the structure of the antigen, it could limit its effectiveness as a capture
molecule. This is particularly true for capture of antibodies generated against
the secondary structure of the antigen. A loss of signal could also result if the
coupled ligand leaches from the magnetic beads, which would also adversely
affect the shelf life of prepared beads. It is important to consider whether
conjugation chemistry introduces a charged group to the beads that could
cause nonspecific binding of either proteins and/or the reporter
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oligonucleotide to the beads. A final consideration is a linkage chemistry that
could alter the structure of the beads such as promoting aggregation and/or
adversely affecting their binding characteristics. These are all important
considerations for design of antigen coupling to the magnetic beads that with
testing of each functional group reactivity could provide for a more sensitive
assay.
The types of functional groups found in antigenic proteins typically
used for attachment to magnetic beads and available in a commercial format
include primary amines, sulfhydryls and carboxylic acids [214]. The most
common functional target for immobilizing protein molecules is the amine
group (–NH2). This group exists at the N-terminus of each polypeptide chain
and in the side chain of lysine residues. Due to its positive charge at
physiological conditions (pH 7.0), primary amines are usually located on
protein surfaces and allow for bead conjugation without denaturing the protein
structure [215]. This is highly advantageous so as to minimize impacts on
antigen secondary structure that could hinder antibody recognition. The
limitation to the amine group coupling is that different antigens have different
numbers of amine groups and hence it is difficult to maintain a uniform
coupling efficiency across distinct antigens.
In addition to amines, the thiol group can be used for direct coupling
reactions using sulfhydryl (–SH) groups which exist in the side chain of
cysteine [215]. Cysteines are joined together between their side chains via
disulfide bonds (–S–S–) and provide secondary and tertiary structure to
proteins. As opposed to amine groups that can be directly coupled to beads,
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sulfhydryl groups must be reduced to make them available for immobilization.
Sulfhydryl groups typically are present in fewer numbers than primary amines
providing a potential method of selective and directional immobilization. A
repeated number of sulfhydryl groups (cysteine residues) could be added to
the terminus of an antigen providing a conjugation that will likely orient every
protein molecule in the same way on the beads. The only drawback to this
type of coupling reaction is the need to reduce naturally occurring disulfide
bonds that may be present in the primary sequence of the antigen to make
sulfhydryl groups available for covalent attachment.
In addition to amines and sulfhydryl groups, proteins also have
carboxyl groups (–COOH) that can also be utilized for conjugation to beads
[215]. This is based on attachment at the C-terminus of each polypeptide
chain and any amino acid residues of either aspartic acid or glutamic acid.
Due to their charge and similarity to amine groups, carboxyl groups are
usually found on the surface of proteins making them readily available for
attachment. Carboxylic acids can be used to link antigens to commercially
available beads through the use of an intermediary reaction. This method
does typically require activation with a water-soluble cross-linker making this
linkage a slightly more technically complex. The advantage to this method of
antigen conjugation to beads is the resulting bead surface has a low nonspecific binding of nucleic acids, which could minimize non-specific
interactions with the iPCR reporter oligonucleotide. Overall, examination of
different antigen conjugation methods has the potential to improve the existing
iPCR protocol through reduction of the background signal with minimized
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effects on the true signal thus providing overall increased sensitivity through
reduction of non-specific interactions.
In addition to antigen coupling, the other aspect of iPCR reagent
development that could be improved is assembly of the secondary
antibody/oligonucleotide complex. The existing method utilizes a commercial
process for conjugation of streptavidin to the secondary antibody using a
proprietary one-step process that requires no downstream purification
methodology (Lightning Link Streptavidin, Innova Biosciences, Cambridge,
UK). The reporter oligonucleotide is synthesized with a terminal biotin group
and a bridge between the two molecules is formed through the biotinstreptavidin interaction. Although successful, this method has the potential to
introduce background signal based on unconjugated free oligonucleotide
and/or reporter antibody lacking the oligonucleotide. A more efficient method
would be to avoid the use of bridging molecules and directly conjugate the
oligonucleotide and reporter antibody. This could be accomplished through a
proprietary commercial synthesis (Chimera Biotec, Germany) or a
commercially available kit based on incorporation of an amine group on the 5’
or 3’ end of the oligonucleotide followed by directed antibody conjugation
(Innova biosciences, United Kingdom). Additional methods of
oligonucleotide/antibody conjugation would require analysis to determine the
effect on both the true signal and the background signal.
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Decreasing Noise and Increasing Signal
Most diagnostic assays have an inherent signal to noise ratio. In
immunological-based assays, the signal is generated from the binding of the
reporter molecule to its specific target with the noise due mainly to the binding
of the reporter to any non-specific targets such as the matrix or other proteins.
The higher the signal to noise ratio, the more an assay can sensitively detect
its target above the call threshold. All iPCR methods developed to date have
noise due to inherent background amplification similar to the background
observed with other immuno-specific methods (i.e., ELISA) [127]. Testing of
our iPCR method (data not shown) was undertaken at the preliminary stages
of assay development to both increase the signal and decrease the noise in
our particular assay design (iPCR with magnetic beads, streptavidin/biotin
bridged antibody/oligo). Different methods of bead blocking (Milk, blotto, BSA,
commercial proprietary, etc.) were tested with no detectable change in
background noise. Beads were also pre-incubated with naive serum from the
same (mouse to mouse) as well as different species (rabbit to mouse) again
with no detectable change in signal or background amplification. Additional
experiments explored the potential for background contribution from unbound
oligonucleotide and it was finally determined that, similar to other methods,
the background signal in our iPCR assay predominated from non-specific
binding of the secondary antibody to the magnetic beads.
One possible alternative approach for reducing the iPCR background
signal that remains to be explored is to replace the oligonucleotide-labeled
secondary antibody with a different type of reporter molecule. Protein A,
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Protein G, Protein A/G hybrids and Protein L all bind antibodies with different
affinity based on species and isotype. These proteins have been explored as
antibody reporter conjugates for Lyme disease ELISA based detection in zoo
animals, game animals and hunting dogs [216, 217] and have shown good
specificity for other infectious diseases [218, 219]. With the current optimized
DOC IgG iPCR protocol, the most likely candidate would be Protein A/G but
all antibody binding protein family members could be tested for application to
iPCR detection of host generated antibodies in human serum samples. In
contrast to decreasing the background noise of the assay, increasing the
positive signal has the potential to also provide a more sensitive test. This
could be accomplished by exploring other more sensitive and more complex
reporter systems such as gold nanoparticles [220], electroconduction [221] or
surface plasmon resonance [222]. However, the most applicable to the
existing protocol would be to expand on the number of B. burgdorferi peptides
in the hybrid antigen. This would require mapping the immunodominant
peptides on known B. burgdorferi antigens. Besides the VlsE (C6) and OspC
(PEPC10) antigens, this has only been accomplished on limited B. burgdorferi
antigens to date [223-226]. Future studies aimed at epitope mapping of the
protein panel that performed well with human samples (Chapter 3 Table 4)
has potential to provide additional peptides to enhance the existing DOC
hybrid antigen. It is also possible to predict conserved peptide antigens based
on in-silico alignment of gene sequences from multiple species/strains. For
example, an alignment of DbpA sequences for a number of strains and
species (Figure 18) permits the prediction of a potential conserved B.
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burgdorferi peptide that could be seroreactive. Additional antigens known or
suspected to be seroreactive in humans (Chapter 1) would also provide an
additional source of potential targets.
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Figure 18. The DbpA antigen shows conservation at the Borrelia species level. An alignment of DbpA sequences from multiple
strains for B. burgdorferi (top panel), B. garinii (middle panel) and B. afzelii (bottom panel) show regions of conservation for
each species (gray highlight) that could function as peptide targets for further immuno-PCR development.
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Additional Development and Testing
In addition to work aimed at improving the sensitivity and specificity of
the iPCR assay, it is important to consider practical aspects related to the
future clinical application of iPCR for routine diagnosis of Lyme disease.
Additional development goals include: (1) increasing throughput, (2) more
precisely defining measures of background, sensitivity and specificity, and (3)
broadening the diagnostic capability of the assay.
The current protocol as published requires manual processing of
individual samples. This not only provides for a more laborious and costly
method but introduces the potential for human error. To increase throughput,
a number of commercially available systems (plate washers, robotic liquid
handlers, magnetic bead separators) have been developed for automated
processing of magnetic bead based assays that can function using a 96-well
plate format. A 96-well plate format would not only increase throughput but
also provide more seamless compatibility with downstream qPCR analysis.
Beyond commercially available units, there is the potential to automate the
entire process in a microfluidic-type system that would combine both magnetic
bead capture of host antibodies and PCR signal amplification in a single
enclosed system. By increasing throughput, the efficiency of processing and
more importantly repeatability would make transferring the protocol to a
clinical setting more practical.
A higher throughput and more automated protocol will provide the
opportunity to increase the numbers of samples to attain a statistically
stronger measurement of the healthy human background to contribute to a
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more accurate call threshold. It is also important to analyse an increased
number of samples similar to the types already tested in the CDC research
panels (Lyme early, Lyme late, look-alikes, healthy endemic and nonendemic) to provide a more robust estimate of the specificity and sensitivity of
the iPCR assay. Increasing the number of Lyme patient and healthy samples
tested will increase the overall confidence in assay performance and
potentially move the assay closer towards clinical readiness.
Although it is important to continue to refine the iPCR approach for
application to Lyme disease it is important to emphasize that the existing
protocol is currently designed for testing of human samples suspected of
infection with B. burgdorferi. Additional Borrelia species, B. garinii and B.
afzelii, are known to cause Lyme disease in Europe and the amino acid
sequences of the antigenic proteins from these species may be divergent
from those of B. burgdorferi . Therefore, infections resulting from B. garinii and
B. afzelii may not be detected with the existing DOC antigen IgG iPCR assay.
Testing of the same antigens (DbpA, C6 and PEPC10) from B. garinii and B.
afzelii could provide a useful diagnostic for European Lyme patients but would
require similar validation testing to determine the sensitivity and specificity of
the refined antigen targets. In addition to humans, domestic animals such as
dogs and horses are also known to suffer from Lyme disease as a result of
infection with B. burgdorferi. It would be important to determine whether the
DOC IgG protocol developed for humans would be applicable to Lyme
disease testing in animals. Using the existing protocol, this would simply
require either replacing the secondary reporter antibody with a species
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specific antibody or testing of the newly proposed protein A/G reporter
system. With additional design and development studies, iPCR application for
diagnosis of Lyme disease has broad potential as a diagnostic platform.
In total these future studies will provide insight into the applicability of
iPCR for diagnosis of Lyme disease by optimizing the existing methods and
expanding the protocol for more universal application with the goal of
transferring the assay into a clinical setting for routine testing. This would help
to improve diagnosis and ultimately treatment of a controversial and
potentially debilitating infectious disease.
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